Zip12 antibody 2

By developing antibodies that specifically bind to the extracellular domain of ZIP12, the targeted problems in the treatment and diagnosis of pulmonary hypertension were solved, and effective treatment and non-invasive diagnosis of pulmonary hypertension were achieved.

CN119013294APending Publication Date: 2024-11-22IP2IPO INNOVATIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029030.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-22
Filing Date
2023-03-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing treatments for pulmonary hypertension are limited in effect, lacking specific treatments targeting the ZIP12 protein, and the diagnosis of pulmonary hypertension requires invasive surgery, lacking simple and less invasive new markers.

Method used

Develop antibodies that specifically bind to the extracellular domain of ZIP12, inhibiting their function, and thus for the treatment and diagnosis of hypoxia-induced pulmonary hypertension.

Benefits of technology

Antibodies targeting ZIP12, inhibiting the proliferation of hypoxic-exposed pulmonary vascular smooth muscle cells and the increase of intracellular unstable zinc provide potential therapeutic targets and improving diagnostic methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013294A_ABST
    Figure CN119013294A_ABST
Patent Text Reader

Abstract

The present invention relates to ZIP12 antibodies. The invention extends to compositions, including pharmaceutical compositions and kits, comprising the antibodies. The invention also extends to methods of making and using the antibodies, e.g., in the treatment and diagnosis of hypoxia-related disorders, such as pulmonary arterial hypertension and cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to ZIP12 antibodies, and the invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of preparing and using the antibodies, such as methods for treating and diagnosing hypoxia-related diseases, such as pulmonary hypertension and cancer. Background Art

[0002] Pulmonary hypertension (PH) is a pathological disease characterized by elevated pulmonary artery pressure and remodeling of pulmonary vascular architecture. Current treatments for PH focus primarily on pharmacological manipulation of signaling mechanisms used by vasoactive factors and have limited therapeutic efficacy. There is an unmet medical need for new therapeutic approaches and diagnostics for this potentially fatal disease.

[0003] The typical response of adult mammal pulmonary circulation to hypoxia is vasoconstriction and structural remodeling of pulmonary arterioles, leading to chronic elevation of pulmonary artery pressure (pulmonary hypertension) and chronic elevation of right ventricular hypertrophy. However, some mammals show genetic resistance to hypoxia-induced pulmonary hypertension (WILKINS, MR et al., Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation. 2015, 131, 582-590; ZHAO, L. et al., Right ventricular hypertrophy secondary to pulmonary hypertension is linked to rat chromosome 17: evaluation of cardiac ryanodine Ryr2 receptor as a candidate. Circulation. 2001, 103, 442-447; RHODES, J., Comparative physiology of hypoxic pulmonary hypertension: historical clues from brisket disease. Journal of applied physiology. 2005, 98, 1092-1100). The inventors of the present invention have previously reported that the Fisher 344 (F344) rat strain is resistant to hypoxia-induced pulmonary hypertension compared to the Wistar Kyoto (WKY) rat strain (ZHAO, L. et al., Right ventricular hypertrophy secondary to pulmonary hypertension is linked to rat chromosome 17: evaluation of cardiac ryanodine Ryr2 receptor as a candidate. Circulation. 2001, 103, 442-447). However, the reason for this resistance is still unclear.

[0004] The inventors have also previously used an appropriate breeding program and comparative genomics to exploit this variation in rats and have identified the Slc39a12 gene as a master regulator of hypoxia-induced pulmonary vascular remodeling. Slc39a12 encodes the zinc transporter ZIP12. They found that in remodeled pulmonary arterioles in rats, cows, and humans susceptible to hypoxia-induced pulmonary hypertension, the expression of ZIP12 was increased in many cell types, including endothelial cells, smooth muscle cells, and interstitial cells. The inventors have shown that the expression of ZIP12 in pulmonary vascular smooth muscle cells is hypoxia-dependent and that targeted inhibition of ZIP12 suppresses the increase in intracellular labile zinc in hypoxia-exposed pulmonary vascular smooth muscle cells and inhibits their proliferation in culture. The inventors have also previously demonstrated that genetic disruption of ZIP12 expression attenuates the development of pulmonary hypertension in rats raised in a hypoxic environment.

[0005] However, to date, there is no specific therapeutic approach that targets the ZIP12 protein, which the inventors believe could provide an improved means of treating pulmonary hypertension. Furthermore, diagnosis of pulmonary hypertension typically requires invasive procedures such as right heart catheterization and echocardiography. Therefore, it would also be desirable to identify new markers of pulmonary hypertension that could be measured by simple and less invasive procedures. Summary of the invention

[0006] The inventors hypothesized that inhibition of ZIP12 could prevent hypoxia-induced proliferation of pulmonary vascular smooth muscle cells (PVSMC) in vitro and ex vivo pulmonary angiogenesis. This identified ZIP12 as a potential new therapeutic target for the treatment of underlying disease mechanisms of pulmonary hypertension, which prompted the inventors to further work on developing antibodies that can target the extracellular domain of ZIP12 to inhibit its function. The anti-ZIP12 activity of these antibodies means that they are themselves useful therapeutic agents that can be used to treat, ameliorate or prevent any hypoxia-induced or hypoxia-related condition, particularly, but not limited to, pulmonary hypertension.

[0007] Accordingly, in the first aspect of the present invention, an antibody or an antigen-binding fragment thereof is provided, which specifically binds to the extracellular domain of ZIP12 and recognizes an epitope comprising ADLLQVLSAGDHPPHNHSRS (SEQ ID No: 252) or a variant or fragment thereof or consisting of ADLLQVLSAGDHPPHNHSRS or a variant or fragment thereof, or preferably, it recognizes an epitope comprising LLQVLSAGDHPPHNHSRS (SEQ ID No: 1) or a variant or fragment thereof or consisting of LLQVLSAGDHPPHNHSRS or a variant or fragment thereof.

[0008] On the other hand, an antibody or an antigen-binding fragment thereof is provided, which specifically binds to the extracellular domain of ZIP12 and recognizes an epitope comprising LLQVLSAGDHPPHNHSRS (SEQ ID No: 1) or a variant or fragment thereof or consisting of LLQVLSAGDHPPHNHSRS or a variant or fragment thereof.

[0009] As shown in the examples ( Figure 8 As shown in Figure 2, the inventors have determined that the extracellular region or domain of the ZIP12 protein is key to its function, and therefore have developed antibodies that can bind to and inhibit the function of ZIP12. Figure 9b As shown, the present inventors have developed a number of antibodies and have demonstrated that these antibodies specifically target the extracellular domain and inhibit the function of ZIP12.

[0010] Preferably, the antibody or antigen-binding fragment thereof of the present invention can inhibit the function of ZIP12. Preferably, the antibody or antigen-binding fragment thereof of the present invention can inhibit the function of ZIP12, thereby inhibiting the increase of intracellular labile zinc in hypoxia-exposed pulmonary vascular smooth muscle cells and their proliferation in culture.

[0011] The epitope may be provided herein as SEQ ID No: 252:

[0012] ADLLQVLSAGDHPPHNHSRS

[0013] [SEQ ID No:252]

[0014] Preferably, the epitope may be provided herein as SEQ ID No: 1, as shown below:

[0015] LLQVLSAGDHPPHNHSRS

[0016] [SEQ ID No:1]

[0017] like Fig.10 As shown in Figure C, the present inventors determined that the sequence ADLLQ (SEQ ID No: 253) is a common motif found in several candidate epitopes.

[0018] Preferably, therefore, the epitope may be provided herein as SEQ ID No: 253, as follows:

[0019] ADLLQ

[0020] [SEQ ID No:253]

[0021] Accordingly, in one embodiment, the antibody or antigen-binding fragment thereof recognizes an epitope comprising or consisting of ADLLQ (SEQ ID No: 253) or a variant or fragment thereof.

[0022] In one embodiment, ZIP12 may be represented by Genbank ID No: NP-001138667, which is provided herein as SEQ ID No: 2, as shown below:

[0023] MCFRTKLSVSWVPLFLLLSRVFSTETDKPSAQDSRSRGSSGQPADLLQVLSAGDHPPHNHSRSLIKTLLEKTGCPRRRNGMQGDCNLCFEPDALLLIAGGNFEDQLREEVVQRVSLLLLYYIIHQEEICSSKLNMSNKEYKFYLHSLLSLRQDEDSSFLSQNETEDILAFTR QYFDTSQSQCMETKTLQKKSGIVSSEGANESTLPQLAAMIITLSLQGVCLGQGNLPSPDYFTEYIFSSLNRTNTLRLSELDQLLNTLWTRSTCIKNEKIHQFQRKQNNIITHDQDYSNFSSSMEKESEDGPVSWDQTCFSARQLVEIFLQKGLSLISKEDFKQMSPGIIQQLL SCSCHLPKDQQAKLPPTTLEKYGYSTVAVTLLTLGSMLGTALVLFHSCEENYRLILQLFVGLAVGTLSGDALLHLIPQVLGLHKQEAPEFGHFHESKGHIWKLMGLIGGIHGFFLIEKCFILLVSPNDKQGLSLVNGHVGHSHHLALNSELSDQAGRGKSASTIQLKSPEDSQ AAEMPIGSMTASNRKCKAISLLAIMILVGDSLHNFADGLAIGAAFSSSSSESGVTTTIAILCHEIPHEMGDFAVLLSSGLSMKTAILMNFISSLTAFMGLYIGLSVSADPCVQDWIFTVTAGMFLYLSLVEMLPEMTHVQTQRPWMMFLLQNFGLILGWLSLLLLAIYEQNIKI

[0024] [SEQ ID No:2]

[0025] The antibody or antigen-binding fragment thereof can bind to an epitope that is a portion of SEQ ID No: 2 or a fragment or variant thereof.

[0026] Preferably, the antibody or its antigen-binding fragment binds to an epitope contained in the amino acid sequence of SEQ ID No: 252 and / or SEQ ID No: 1. Preferably, the antibody or its antigen-binding fragment binds to one or more amino acids contained in SEQ ID No: 252 and / or SEQ ID No: 1, or fragments or variants thereof. Preferably, the antibody or its antigen-binding fragment binds to any 5, 6 or 7 amino acids present in SEQ ID No: 252 and / or SEQ ID No: 1, or variants or fragments thereof. Preferably, the antibody or its antigen-binding fragment binds to any 8, 9 or 10 amino acids present in SEQ ID No: 252 and / or SEQ ID No: 1, or variants or fragments thereof. Preferably, the antibody or its antigen-binding fragment binds to any 11, 12 or 13 amino acids present in SEQ ID No: 252 and / or SEQ ID No: 1, or variants or fragments thereof. Preferably, the antibody or its antigen-binding fragment binds to any 14, 15 or 16 amino acids present in SEQ ID No: 252 and / or SEQ ID No: 1, or variants or fragments thereof. Preferably, the antibody or antigen-binding fragment thereof binds to any 17 or 18 amino acids present in SEQ ID No: 252 and / or SEQ ID No: 1, or variants or fragments thereof.

[0027] Epitopes can be linear or conformational. The term "linear epitope" may refer to an epitope consisting of amino acid residues that together form a sequence in the primary sequence of a protein antigen, i.e., a sequential or continuous epitope. A linear epitope may be present on a folded ZIP12.

[0028] The term "conformational epitope" may refer to an epitope composed of amino acid residues, at least some of which are separated from other residues in the primary sequence of the protein antigen, but which are assembled together in a three-dimensional structure and recognized by antibodies, i.e., a discontinuous or non-sequential epitope.

[0029] according to Figure 8 Based on the data obtained in , the inventors believe that the epitope of the antibody or its antigen-binding fragment is at least partially linear. In fact, the antibody is likely to bind to a predominantly linear epitope. However, the antibody or its antigen-binding fragment may not bind to every amino acid in SEQ ID No: 252 and / or SEQ ID No: 1.

[0030] ZIP12, ZIP13, and ZIP4 are all zinc transporters. However, ZIP4 is not involved in the pathogenesis of pulmonary hypertension, but plays an important role in tissue balance, metabolism, development, and immunity. In addition, ZIP13 has been shown to regulate zinc and smad signaling in cells, which is important for BMP / TGF-beta signaling (see Fakuda et al., J Biol Inorg Chem, 2011). Impaired BMP signaling is known to be associated with pulmonary hypertension, as shown in Morrell et al Nature Reviews Cardiology, 2015. Therefore, inhibiting ZIP13 will lead to reduced zinc concentrations, which may impair BMP signaling and cause pulmonary hypertension, rather than cure pulmonary hypertension.

[0031] Therefore, it is important that the antibodies of the present invention directed against ZIP12 are specific and have no or little cross-reactivity with ZIP13 and / or ZIP4, as this could result in significant undesired off-target effects.

[0032] Accordingly, preferably, the antibody or antigen-binding fragment thereof of the present invention does not substantially bind to human ZIP13. Preferably, the antibody or antigen-binding fragment thereof of the present invention has no cross-reactivity with human ZIP13.

[0033] In one embodiment, ZIP13 can be represented by Gene ID No: 91252, provided herein as SEQ ID No: 3, as shown below:

[0034] MPGCPCPGCGMAGPRLLFLTALALELLERAGGSQPALRSRGTATACRLDNKESESWGALLSGERLDTWICSLLGSLMVGLSGVFPLLVIPLEMGTMLRSEAGAWRLKQLLSFALGGLGNVFLHLLPEAWAYTCSASPGGEGQSLQQQQQLGLWVIAGILTFLALEKMFLDSKEEGTSQAPNKDP TAAAAALNGGHCLAQPAAEPGLGAVVRSIKVSGYLNLLANTIDNFTHGLAVAASFLVSKKIGLLTTMAILLHEIPHEVGDFAILLRAGFDRWSAAKLQLSTALGGLLGAGFAICTQSPKGVVGCSPAAEETAAWVLPFTSGGFLYIALVNVLPDLLEEEDPWRSLQQLLLLCAGIVVMVLFSLFVD

[0035] [SEQ ID No:3]

[0036] Thus, preferably, the antibody or antigen-binding fragment thereof does not bind to the sequence substantially set out in SEQ ID No: 3 or a variant or fragment thereof.

[0037] Furthermore, preferably, the antibody or antigen-binding fragment thereof of the present invention does not substantially bind to human ZIP4. Preferably, the antibody or antigen-binding fragment thereof of the present invention has no cross-reactivity with human ZIP4.

[0038] In one embodiment, ZIP4 can be represented by Gene ID No: NP-570901, provided herein as SEQ ID No: 4, as shown below:

[0039] MASLVSLELGLLLAVLVVTATASPPAGLLSLLTSGQGALDQEALGGLLNTLADRVHCANGPCGKCLSVEDALGLGEPEGSGLPPGPVLEARYVARLSAAAVLYLSNPEGTCEDARAGLWASHADHLLALLESPKALTPGLSWLLQRMQARAAGQTPKTACV DIPQLLEEAVGAGAPGSAGGVLAALLDHVRSGSCFHALPSPQYFVDFVFQQHSSEVPMTLAELSALMQRLGVGREAHSDHSHRHRGASSRDPVPLISSSNSSSVWDTVCLSARDVMAAYGLSEQAGVTPEAWAQLSPALLQQQLSGACTSQSRPPVQDQLSQ SERYLYGSLATLLICLCAVFGLLLLTCTGCRGVTHYILQTFLSLAVGALTGDAVLHLTPKVLGLHTHSEEGLSPQPTWRLLAMLAGLYAFFLFENLFNLLLPRDPEDLEDGPCGHSSHSHGGHSHGVSLQLAPSELRQPKPPHEGSRADLVAEESPELLNPE PRRLSPELRLLPYMITLGDAVHNFADGLAVGAAFASSWKTGLATSLAVFCHELPHELGDFAALLHAGLSVRQALLLNLASALTAFAGLYVALAVGVSEESEAWILAVATGLFLYVALCDMLPAMLKVRDPRPWLLFLLHNVGLLGGWTVLLLLSLYEDDITF

[0040] [SEQ ID No:4]

[0041] Thus, preferably, the antibody or antigen-binding fragment thereof does not bind to the sequence substantially set out in SEQ ID No: 4 or a variant or fragment thereof.

[0042] Preferably, the antibody or antigen-binding fragment thereof binds to human and / or cynomolgus monkey ZIP12. Preferably, the antibody or antigen-binding fragment thereof does not bind to canine and / or porcine ZIP12.

[0043] The present invention extends to whole antibodies (i.e., immunoglobulins) that are immunospecific for the ZIP12 extracellular epitope, which comprises SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof, as well as to antigen-binding fragments or regions of the corresponding full-length antibodies.

[0044] The antibody or its antigen-binding fragment can be monovalent, divalent or multivalent. A monovalent antibody is a dimer (HL) comprising a heavy chain (H) connected to a light chain (L) by a disulfide bridge. A divalent antibody is a tetramer (H2L2) comprising two dimers connected by at least one disulfide bridge. Multivalent antibodies can also be produced, for example by connecting multiple dimers. The basic structure of an antibody molecule includes two identical light chains and two identical heavy chains, which are non-covalently bound and can be connected by disulfide bonds. Each heavy chain and light chain contains an amino-terminal variable region of approximately 110 amino acids, with constant sequences in the rest of the chain. The variable region includes several hypervariable regions, or complementary determining regions (CDRs), which form the antigen binding site of the antibody molecule and determine its specificity for the antigen, i.e., the extracellular part of ZIP12, or a variant or fragment thereof (such as an epitope). On both sides of the CDRs of the heavy and light chains is a framework region, which is a relatively conserved amino acid sequence used to anchor and orient the CDRs. Antibody fragments may include bispecific antibodies (BsAb) or chimeric antigen receptors (CARs).

[0045] The heavy chain constant region usually consists of three domains, C H1 , C H2 and C H3 Each light chain generally includes a light chain variable region (V L ) and a light chain constant region. The light chain constant region usually includes a domain, abbreviated as C L .

[0046] Each heavy and light chain generally includes three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. CDRs are involved in antigen binding and confer antigen specificity and binding affinity to antibodies. See Kabat et al., Sequences of Proteins of Immunological Interest 5 th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, the contents of which are incorporated by reference in their entirety.

[0047] The heavy chains of any vertebrate can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also known as α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses based on differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0048] The light chain of any vertebrate can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.

[0049] The constant region consists of one of five heavy chain sequences (μ, γ, ζ, α or ε) and one of two light chain sequences (κ or λ). The heavy chain constant region sequence determines the antibody's isotype and the effector functions of the molecule.

[0050] Preferably, the antibody or antigen-binding fragment thereof is isolated or purified.

[0051] In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises a polyclonal antibody or an antibody-binding fragment thereof.The antibody or antigen-binding fragment thereof can be produced in rabbits, mice or rats.

[0052] Preferably, the antibody or antigen-binding fragment thereof is obtained by immunizing a host animal with an extracellular epitope of ZIP12 or a variant or fragment thereof, and then collecting the antibody or antigen-binding fragment thereof, wherein the extracellular epitope of ZIP12 comprises SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof, or consists of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof. The host animal may be a rabbit.

[0053] In another preferred embodiment, the antibody or its antigen-binding fragment comprises a monoclonal antibody or its antibody-binding fragment. Preferably, the antibody of the present invention is a human antibody. As used herein, the term "human antibody" may refer to an antibody, such as a monoclonal antibody, comprising substantially the same heavy and light chain CDR amino acid sequences as those found in a specific human antibody that exhibits immunospecificity to the extracellular portion of ZIP12 or a variant or fragment thereof. Amino acid sequences substantially identical to the heavy or light chain CDRs exhibit considerable sequence identity compared to a reference sequence. This identity is explicitly referred to as or identifiable as an amino acid sequence representing a specific human antibody. Substantially identical heavy and light chain CDR amino acid sequences may have, for example, minor modifications or conservative substitutions of amino acids. Such human antibodies maintain their function of selectively binding to the extracellular epitope of ZIP12, which comprises SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof, or is composed of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof.

[0054] The term "human monoclonal antibody" may include monoclonal antibodies having substantially or completely human CDR amino acid sequences, which are produced, for example, by recombinant methods, such as by phage libraries, lymphocytes, or hybridoma cells.

[0055] The term "monoclonal antibody" refers to an antibody from a substantially homogeneous antibody population. A substantially homogeneous antibody population includes substantially similar antibodies, and binds to the same epitope, except for variants that may generally occur during the production of monoclonal antibodies. Such variants are generally present only in small amounts. Monoclonal antibodies are generally obtained by including a process for selecting a single antibody from a variety of antibodies. For example, the selection process may be to select a unique clone from a plurality of clones, such as a hybridoma clone library, a phage clone library, a yeast clone library, a bacterial clone library or other recombinant DNA clone libraries. The selected antibody may be further altered, for example, to improve affinity to the target (by so-called "affinity maturation"), humanize the antibody, improve its yield in cell culture, and / or reduce its immunogenicity in a subject.

[0056] The term "humanized antibody" may refer to an antibody from a non-human species, such as a mouse or rabbit, whose protein sequence has been modified to increase its similarity to antibodies naturally produced by humans.

[0057] The antibody may be a recombinant antibody. The term "recombinant human antibody" may include human antibodies produced using recombinant DNA technology.

[0058] The term "antigen binding region" may refer to a region of an antibody that has a specific binding affinity for its target antigen, such as an extracellular epitope of ZIP12, which comprises or consists of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof. Preferably, the fragment is an epitope. The antigen binding region may be a hypervariable CDR or a functional portion thereof. The term "functional portion" of a CDR may refer to a sequence within a CDR that shows a specific affinity for a target antigen. The functional portion of a CDR may include an extracellular epitope that specifically binds to ZIP12, which comprises or consists of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof.

[0059] The term "CDR" may refer to the hypervariable regions in the heavy and light chains. There may be one, two, three or more CDRs in each of the heavy and light chains of an antibody. Usually, there are at least three CDRs on each chain, which, when configured together, form an antigen binding site, i.e., a three-dimensional binding site for antigen binding or specific reaction. However, it is speculated that there may be four CDRs in the heavy chain of some antibodies.

[0060] The definition of CDR also includes overlaps or subgroups of amino acid residues when compared to each other. The exact number of residues comprising a particular CDR or its functional portion will vary depending on the sequence and size of the CDR. Given the variable region amino acid sequence of an antibody, one skilled in the art can routinely determine which residues comprise a particular CDR.

[0061] The amino acid sequence boundaries of a CDR can be determined by using any of a number of known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001 309:657-70 ("AHo" numbering scheme).

[0062] The term "functional fragment" of an antibody may refer to a portion of an antibody that retains functional activity. Functional activity may be, for example, antigen binding activity or specificity. Functional activity may also be, for example, an effector function provided by an antibody constant region. The term "functional fragment" is also intended to include, for example, fragments produced by protease digestion or reduction of human monoclonal antibodies and recombinant DNA methods known to those skilled in the art. Human monoclonal antibody functional fragments include, for example, single heavy or light chains and fragments thereof, such as VL, VH, and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments, such as FF(ab')2; single-chain v (scFv); and Fc fragments.

[0063] The term "VL fragment" may refer to a light chain fragment of a human monoclonal antibody, which includes all or part of the light chain variable region, including CDRs. The VL fragment may further include a light chain constant region sequence.

[0064] The term "VH fragment" may refer to a heavy chain fragment of a human monoclonal antibody, which includes all or part of the heavy chain variable region, including CDRs.

[0065] The term "Fd fragment" may refer to the heavy chain variable region coupled to the first heavy chain constant region (ie, VH and CH-1).

[0066] The "Fd fragment" does not include the light chain, nor the second and third constant regions of the heavy chain.

[0067] The term "Fv fragment" may refer to a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the variable regions of the heavy and light chains, and without the constant regions of the heavy and heavy chains. The variable regions of the heavy and light chains include, for example, CDRs. For example, an Fv fragment includes all or part of the amino terminal variable regions of about 110 amino acids of the heavy and light chains.

[0068] The term "Fab fragment" may refer to a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than an Fv fragment. For example, a Fab fragment includes the variable region, and all or part of the first constant domain of the heavy chain and the light chain. Thus, a Fab fragment additionally includes, for example, about 110 to about 220 amino acid residues of the heavy chain and the light chain.

[0069] The term "Fab' fragment" may refer to a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes all of the light chain, all of the heavy chain variable regions, and all or part of the heavy chain first and second constant domains. For example, a Fab' fragment may additionally include some or all of the 220 to 330 amino acid residues of the heavy chain.

[0070] The term "F(ab')2 fragment" may refer to a bivalent antigen-binding fragment of a human monoclonal antibody. The F(ab')2 fragment includes, for example, all or part of the variable regions of two heavy chains and two light chains, and may further include all or part of the first constant domains of two heavy chains and two light chains.

[0071] The term "single-chain Fv (scFv)" may refer to a fusion of heavy chain (VH) and light chain (VL) variable regions connected to a short linker peptide.

[0072] The term "bispecific antibody (BsAb)" may refer to a bispecific antibody comprising two scFvs linked to each other by a short linker peptide.

[0073] Those skilled in the art will appreciate that the exact boundaries of an antibody fragment are not important, as long as the fragment remains functionally active. Using well-known recombinant methods, those skilled in the art can design polynucleotide sequences to express functional fragments with any endpoints desired for a particular application. Functional fragments of antibodies may comprise fragments having heavy and light chain variable regions substantially identical to those of human antibodies.

[0074] Preferably, with respect to the first aspect of the present invention, the antigen binding fragment thereof has immunospecificity for an extracellular epitope of ZIP12 comprising SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof. The antigen binding fragment may comprise any fragment selected from VH, VL, Fd, Fv, Fab, Fab', scFv, F(ab')2 and Fc fragments.

[0075] The antigen-binding fragment may be a single domain antibody (sdAb), also known as a nanobody, which is understood by those skilled in the art to be an antibody fragment consisting of a single monomeric variable antibody domain.

[0076] The antigen binding fragment may comprise any one of the antigen binding region sequences of VL, any one of the antigen binding region sequences of VH, or a combination of the VL and VH antigen binding regions of a human antibody. The appropriate number and combination of VH and VL antigen binding region sequences can be determined by a person skilled in the art based on the desired affinity and specificity and the intended use of the antigen binding fragment. Functional fragments or antigen binding fragments of antibodies can be easily produced and separated using methods well known to those skilled in the art. These methods include, for example, proteolytic methods, recombinant methods, and chemical synthesis. Proteolytic methods for separating functional fragments include using human antibodies as starting materials. Enzymes suitable for proteolysis of human immunoglobulins may include, for example, papain and pepsin. A person skilled in the art can easily select a suitable enzyme, depending on, for example, whether a monovalent or divalent fragment is required. For example, papain cleavage produces two monovalent Fab' fragments that bind antigens and Fc fragments. For example, pepsin cleavage produces a divalent F(ab') fragment. The F(ab')2 fragment of the present invention can be further reduced using, for example, DTT or 2-mercaptoethanol to produce two monovalent Fab' fragments.

[0077] Functional or antigen-binding fragments of antibodies produced by proteolysis can be purified by affinity and column chromatography procedures. For example, undigested antibody and Fc fragments can be removed by binding to protein A. In addition, functional fragments can be purified by their charge and size, for example using ion exchange and gel filtration chromatography. Such methods are well known to those skilled in the art.

[0078] Antibodies or their antigen-binding fragments can be produced by recombinant methods. Preferably, polynucleotides encoding the desired regions of the heavy and light chains of the antibody are first isolated. Such regions may include, for example, all or part of the variable regions of the heavy and light chains. Preferably, such regions may particularly include the antigen-binding regions of the heavy and light chains, preferably antigen-binding sites, most preferably CDRs.

[0079] The polynucleotides encoding antibodies or antigen-binding fragments thereof according to the present invention can be produced using methods known to those skilled in the art. The polynucleotides encoding antibodies or antigen-binding fragments can be directly synthesized by oligonucleotide synthesis methods known in the art. Alternatively, recombinant methods known in the art can be used to synthesize and connect smaller fragments to form larger functional fragments.

[0080] As used herein, the term "immunological specificity" may refer to the ability of the binding region of an antibody or an antigen-binding fragment thereof to immunologically react with an extracellular epitope of ZIP12 by binding to it, and the extracellular epitope of ZIP12 comprises SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof. The antibody or antigen-binding fragment thereof may preferably selectively interact with an antigen (i.e., an extracellular epitope of ZIP12 comprising SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof, or consisting of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof), and the affinity constant for the antigen is about 10 -5 Up to 10 -13 M -1 , preferably 10 -6 Up to 10 -9 M -1 , even more preferably 10 -10 Up to 10 -12 M -1 The antibody or antigen-binding fragment thereof preferably does not substantially bind to ZIP4 and / or ZIP13 such that the affinity constant is greater than about 10 -10 M -1 , 10 -9 M -1 , 10 -8 M -1 , 10 -7 M -1 or 10 -6 M -1 , preferably greater than 10 -5 M -1 , 10 -4 M -1 or 10 -3 M -1 , even more preferably 10 -2 M -1 , 10 -1 M -1 or 10 -2 M -1 , most preferably 10 +1 M -1 , 10 +2 M -1 or 10 +3 M -1 .

[0081] The term "immune response" may refer to the ability of the binding region to induce an immune response when binding to an extracellular epitope of ZIP12, wherein the extracellular epitope of ZIP12 comprises SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof, or consists of SEQ ID No: 252 and / or SEQ ID No: 1 or a variant or fragment thereof.

[0082] The term "epitope" may refer to any region of an antigen that has the ability to elicit and bind to the binding region of an antibody or antigen-binding fragment thereof.

[0083] Thus, the antibody or antigen-binding fragment thereof may comprise a heavy chain. The heavy chain may be selected from IgA, IgD, IgE, IgG and IgM. Preferably, the heavy chain is IgG. Preferably, the heavy chain is IgA.

[0084] The heavy chain may be IgG1. The heavy chain may be IgG2. The heavy chain may be IgG3. The heavy chain may be IgG4. The heavy chain may be IgA1. The heavy chain may be IgA2.

[0085] As described in the Examples and Figure 1 As shown in , the inventors have developed an antibody candidate that binds to the extracellular domain of ZIP12 (referred to herein as 51B12) that is able to target and inhibit the function of ZIP12. The six CDR, VH and VL sequences of this so-called "51B12-parent" antibody are summarized in Figure 9a The inventors then performed affinity maturation on the "51B12-parent" antibody to generate new variants or mutants.

[0086] As described in Example 1, 8 or 9 mutants were designed for each CDR residue in the three heavy CDRs and light CDRs. For variable heavy chain (VH) CDR variants, the variable regions were synthesized and cloned into an expression vector containing an invalid human IgG1 of Fc. For variable light chain (VL) CDR variants, the variable regions were synthesized and cloned into an expression vector containing a human kappa light chain constant region.

[0087] Figure 9bA table is shown, summarizing the sequences of 26 different affinity matured antibody embodiments derived from "51B12-parent". The first row in the table represents the corresponding sequence (six CDRs, VH and VL) of the affinity mature variant of 51B12-parent, referred to as "H3_W99H_L1", wherein the CDR-H3 sequence is identical to the parent except the W99H amino acid exchange, and the CDR-L1 CDR is as shown in the table. The second row in the table represents the corresponding sequence of the affinity mature variant of 51B12-parent, referred to as "H3_W99H_L2", wherein the CDR-H3 sequence is identical to the parent except the W99H amino acid exchange, and the CDR-L2 CDR is as shown in the table, and so on.

[0088] Each of these affinity matured variants will be described below according to its sequence.

[0089] H3_W99H_L1

[0090] Accordingly, in one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_W99H_L1.

[0091] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 13, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 14, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 15, or a variant or fragment thereof.

[0092] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 13, a CDR-H2 domain comprising or consisting of SEQ ID No: 14, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 15. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 13, a CDR-H2 domain comprising or consisting of SEQ ID No: 14, and a CDR-H3 domain comprising or consisting of SEQ ID No: 15.

[0093] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 19 or a variant or fragment thereof.

[0094] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain, which comprises or consists of a sequence substantially set forth in SEQ ID No: 16, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain, which comprises or consists of a sequence substantially set forth in SEQ ID No: 17, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain, which comprises or consists of a sequence substantially set forth in SEQ ID No: 18, or a variant or fragment thereof.

[0095] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 16, a CDR-L2 domain comprising or consisting of SEQ ID No: 17, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 18. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 16, a CDR-L2 domain comprising or consisting of SEQ ID No: 17, and a CDR-L3 domain comprising or consisting of SEQ ID No: 18.

[0096] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 20 or a variant or fragment thereof.

[0097] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0098] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 13, a CDR-H2 domain comprising or consisting of SEQ ID No: 14, a CDR-H3 domain comprising or consisting of SEQ ID No: 15, a CDR-L1 domain comprising or consisting of SEQ ID No: 16, a CDR-L2 domain comprising or consisting of SEQ ID No: 17, and a CDR-L3 domain comprising or consisting of SEQ ID No: 18.

[0099] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 19 and a light chain variable region comprising or consisting of SEQ ID No: 20.

[0100] H3_W99H_L2

[0101] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_W99H_L2.

[0102] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 21 or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 22 or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 23 or a variant or fragment thereof.

[0103] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 21, a CDR-H2 domain comprising or consisting of SEQ ID No: 22, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 23. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 21, a CDR-H2 domain comprising or consisting of SEQ ID No: 22, and a CDR-H3 domain comprising or consisting of SEQ ID No: 23.

[0104] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 27 or a variant or fragment thereof.

[0105] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 24, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 25, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 26, or a variant or fragment thereof.

[0106] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.

[0107] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 28 or a variant or fragment thereof.

[0108] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0109] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 21, a CDR-H2 domain comprising or consisting of SEQ ID No: 22, a CDR-H3 domain comprising or consisting of SEQ ID No: 23, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.

[0110] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 27 and a light chain variable region comprising or consisting of SEQ ID No: 28.

[0111] H3_W99VL-par

[0112] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_W99H_VL-par.

[0113] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 29, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 30, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 31, or a variant or fragment thereof.

[0114] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, and a CDR-H3 domain comprising or consisting of SEQ ID No: 31.

[0115] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 35 or a variant or fragment thereof.

[0116] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 32, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 33, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 34, or a variant or fragment thereof.

[0117] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 33, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 34. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 33, and a CDR-L3 domain comprising or consisting of SEQ ID No: 34.

[0118] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 36 or a variant or fragment thereof.

[0119] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0120] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No:29, a CDR-H2 domain comprising or consisting of SEQ ID No:30, a CDR-H3 domain comprising or consisting of SEQ ID No:31, a CDR-L1 domain comprising or consisting of SEQ ID No:32, a CDR-L2 domain comprising or consisting of SEQ ID No:33, and a CDR-L3 domain comprising or consisting of SEQ ID No:34.

[0121] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 35 and a light chain variable region comprising or consisting of SEQ ID No: 36.

[0122] H2_T56H_L1

[0123] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T56H_L1.

[0124] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 37, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 38, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 39, or a variant or fragment thereof.

[0125] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 37, a CDR-H2 domain comprising or consisting of SEQ ID No: 38, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 39. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 37, a CDR-H2 domain comprising or consisting of SEQ ID No: 38, and a CDR-H3 domain comprising or consisting of SEQ ID No: 39.

[0126] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 43 or a variant or fragment thereof.

[0127] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 40, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 41, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 42, or a variant or fragment thereof.

[0128] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 40, a CDR-L2 domain comprising or consisting of SEQ ID No: 41, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 42. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 40, a CDR-L2 domain comprising or consisting of SEQ ID No: 41, and a CDR-L3 domain comprising or consisting of SEQ ID No: 42.

[0129] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 44 or a variant or fragment thereof.

[0130] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0131] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 37, a CDR-H2 domain comprising or consisting of SEQ ID No: 38, a CDR-H3 domain comprising or consisting of SEQ ID No: 39, a CDR-L1 domain comprising or consisting of SEQ ID No: 40, a CDR-L2 domain comprising or consisting of SEQ ID No: 41 and a CDR-L3 domain comprising or consisting of SEQ ID No: 42.

[0132] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 43 and a light chain variable region comprising or consisting of SEQ ID No: 44.

[0133] T2_T57H_L1

[0134] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as T2_T57H_L1.

[0135] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 45, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 46, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 47, or a variant or fragment thereof.

[0136] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 45, a CDR-H2 domain comprising or consisting of SEQ ID No: 46, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 47. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 45, a CDR-H2 domain comprising or consisting of SEQ ID No: 46, and a CDR-H3 domain comprising or consisting of SEQ ID No: 47.

[0137] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 51 or a variant or fragment thereof.

[0138] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 48, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 49, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 50, or a variant or fragment thereof.

[0139] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 48, a CDR-L2 domain comprising or consisting of SEQ ID No: 49, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 50. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 48, a CDR-L2 domain comprising or consisting of SEQ ID No: 49, and a CDR-L3 domain comprising or consisting of SEQ ID No: 50.

[0140] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 52 or a variant or fragment thereof.

[0141] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0142] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No:45, a CDR-H2 domain comprising or consisting of SEQ ID No:46, a CDR-H3 domain comprising or consisting of SEQ ID No:47, a CDR-L1 domain comprising or consisting of SEQ ID No:48, a CDR-L2 domain comprising or consisting of SEQ ID No:49, and a CDR-L3 domain comprising or consisting of SEQ ID No:50.

[0143] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No:51 and a light chain variable region comprising or consisting of SEQ ID No:52.

[0144] H2_Y60K_L1

[0145] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_Y60K_L1.

[0146] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 53, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 54, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 55, or a variant or fragment thereof.

[0147] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 53, a CDR-H2 domain comprising or consisting of SEQ ID No: 54, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 55. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 53, a CDR-H2 domain comprising or consisting of SEQ ID No: 54, and a CDR-H3 domain comprising or consisting of SEQ ID No: 55.

[0148] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 59 or a variant or fragment thereof.

[0149] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 56, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 57, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 58, or a variant or fragment thereof.

[0150] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 56, a CDR-L2 domain comprising or consisting of SEQ ID No: 57, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 58. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 56, a CDR-L2 domain comprising or consisting of SEQ ID No: 57, and a CDR-L3 domain comprising or consisting of SEQ ID No: 58.

[0151] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 60 or a variant or fragment thereof.

[0152] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0153] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No:53, a CDR-H2 domain comprising or consisting of SEQ ID No:54, a CDR-H3 domain comprising or consisting of SEQ ID No:55, a CDR-L1 domain comprising or consisting of SEQ ID No:56, a CDR-L2 domain comprising or consisting of SEQ ID No:57, and a CDR-L3 domain comprising or consisting of SEQ ID No:58.

[0154] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No:59 and a light chain variable region comprising or consisting of SEQ ID No:60.

[0155] H2_T63Y_L1

[0156] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T63Y_L1.

[0157] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 61, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 62, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 63, or a variant or fragment thereof.

[0158] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 61, a CDR-H2 domain comprising or consisting of SEQ ID No: 62, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 63. However, preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 61, a CDR-H2 domain comprising or consisting of SEQ ID No: 62, and a CDR-H3 domain comprising or consisting of SEQ ID No: 63.

[0159] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 67 or a variant or fragment thereof.

[0160] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 64, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 65, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 66, or a variant or fragment thereof.

[0161] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 64, a CDR-L2 domain comprising or consisting of SEQ ID No: 65, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 66. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 64, a CDR-L2 domain comprising or consisting of SEQ ID No: 65, and a CDR-L3 domain comprising or consisting of SEQ ID No: 66.

[0162] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of the sequence substantially set forth in SEQ ID No: 68 or a variant or fragment thereof.

[0163] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0164] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No:61, a CDR-H2 domain comprising or consisting of SEQ ID No:62, a CDR-H3 domain comprising or consisting of SEQ ID No:63, a CDR-L1 domain comprising or consisting of SEQ ID No:64, a CDR-L2 domain comprising or consisting of SEQ ID No:65, and a CDR-L3 domain comprising or consisting of SEQ ID No:66.

[0165] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 67 and a light chain variable region comprising or consisting of SEQ ID No: 68.

[0166] H2_K65P_L1

[0167] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_K65P_L1.

[0168] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 69, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 70, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 71, or a variant or fragment thereof.

[0169] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 69, a CDR-H2 domain comprising or consisting of SEQ ID No: 70, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 71. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 69, a CDR-H2 domain comprising or consisting of SEQ ID No: 70, and a CDR-H3 domain comprising or consisting of SEQ ID No: 71.

[0170] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 75 or a variant or fragment thereof.

[0171] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 72, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 73, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 74, or a variant or fragment thereof.

[0172] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 72, a CDR-L2 domain comprising or consisting of SEQ ID No: 73, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 74. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 72, a CDR-L2 domain comprising or consisting of SEQ ID No: 73, and a CDR-L3 domain comprising or consisting of SEQ ID No: 74.

[0173] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 76 or a variant or fragment thereof.

[0174] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0175] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 69, a CDR-H2 domain comprising or consisting of SEQ ID No: 70, a CDR-H3 domain comprising or consisting of SEQ ID No: 71, a CDR-L1 domain comprising or consisting of SEQ ID No: 72, a CDR-L2 domain comprising or consisting of SEQ ID No: 73, and a CDR-L3 domain comprising or consisting of SEQ ID No: 74.

[0176] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 75 and a light chain variable region comprising or consisting of SEQ ID No: 76.

[0177] H2_G66Q_L1

[0178] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_G66Q_L1.

[0179] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 77, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 78, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 79, or a variant or fragment thereof.

[0180] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 77, a CDR-H2 domain comprising or consisting of SEQ ID No: 78, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 79. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 77, a CDR-H2 domain comprising or consisting of SEQ ID No: 78, and a CDR-H3 domain comprising or consisting of SEQ ID No: 79.

[0181] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 83 or a variant or fragment thereof.

[0182] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 80, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 81, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 82, or a variant or fragment thereof.

[0183] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 80, a CDR-L2 domain comprising or consisting of SEQ ID No: 81, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 82. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 80, a CDR-L2 domain comprising or consisting of SEQ ID No: 81, and a CDR-L3 domain comprising or consisting of SEQ ID No: 82.

[0184] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 84 or a variant or fragment thereof.

[0185] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0186] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 77, a CDR-H2 domain comprising or consisting of SEQ ID No: 78, a CDR-H3 domain comprising or consisting of SEQ ID No: 79, a CDR-L1 domain comprising or consisting of SEQ ID No: 80, a CDR-L2 domain comprising or consisting of SEQ ID No: 81, and a CDR-L3 domain comprising or consisting of SEQ ID No: 82.

[0187] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 83 and a light chain variable region comprising or consisting of SEQ ID No: 84.

[0188] H3_M105P_L1

[0189] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_M105P_L1.

[0190] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 85, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 86, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 87, or a variant or fragment thereof.

[0191] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 85, a CDR-H2 domain comprising or consisting of SEQ ID No: 86, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 87. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 85, a CDR-H2 domain comprising or consisting of SEQ ID No: 86, and a CDR-H3 domain comprising or consisting of SEQ ID No: 87.

[0192] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 91 or a variant or fragment thereof.

[0193] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 88, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 89, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 90, or a variant or fragment thereof.

[0194] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 88, a CDR-L2 domain comprising or consisting of SEQ ID No: 89, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 90. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 88, a CDR-L2 domain comprising or consisting of SEQ ID No: 89, and a CDR-L3 domain comprising or consisting of SEQ ID No: 90.

[0195] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 92 or a variant or fragment thereof.

[0196] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0197] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 85, a CDR-H2 domain comprising or consisting of SEQ ID No: 86, a CDR-H3 domain comprising or consisting of SEQ ID No: 87, a CDR-L1 domain comprising or consisting of SEQ ID No: 88, a CDR-L2 domain comprising or consisting of SEQ ID No: 89, and a CDR-L3 domain comprising or consisting of SEQ ID No: 90.

[0198] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No:91 and a light chain variable region comprising or consisting of SEQ ID No:92.

[0199] 51B12_VH_L1

[0200] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as 51B12_VH_L1.

[0201] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 93, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 94, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 95, or a variant or fragment thereof.

[0202] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 93, a CDR-H2 domain comprising or consisting of SEQ ID No: 94, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 95. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 93, a CDR-H2 domain comprising or consisting of SEQ ID No: 94, and a CDR-H3 domain comprising or consisting of SEQ ID No: 95.

[0203] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 99 or a variant or fragment thereof.

[0204] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 96, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 97, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 98, or a variant or fragment thereof.

[0205] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 96, a CDR-L2 domain comprising or consisting of SEQ ID No: 97, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 98. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 96, a CDR-L2 domain comprising or consisting of SEQ ID No: 97, and a CDR-L3 domain comprising or consisting of SEQ ID No: 98.

[0206] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 100 or a variant or fragment thereof.

[0207] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0208] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 93, a CDR-H2 domain comprising or consisting of SEQ ID No: 94, a CDR-H3 domain comprising or consisting of SEQ ID No: 95, a CDR-L1 domain comprising or consisting of SEQ ID No: 96, a CDR-L2 domain comprising or consisting of SEQ ID No: 97, and a CDR-L3 domain comprising or consisting of SEQ ID No: 98.

[0209] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 99 and a light chain variable region comprising or consisting of SEQ ID No: 100.

[0210] H2_T56H_L2

[0211] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T56H_L2.

[0212] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 101 or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 102 or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 103 or a variant or fragment thereof.

[0213] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 101, a CDR-H2 domain comprising or consisting of SEQ ID No: 102, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 103. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 101, a CDR-H2 domain comprising or consisting of SEQ ID No: 102, and a CDR-H3 domain comprising or consisting of SEQ ID No: 103.

[0214] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 107 or a variant or fragment thereof.

[0215] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 104, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 105, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 106, or a variant or fragment thereof.

[0216] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 104, a CDR-L2 domain comprising or consisting of SEQ ID No: 105, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 106. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 104, a CDR-L2 domain comprising or consisting of SEQ ID No: 105, and a CDR-L3 domain comprising or consisting of SEQ ID No: 106.

[0217] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 108 or a variant or fragment thereof.

[0218] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0219] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 101, a CDR-H2 domain comprising or consisting of SEQ ID No: 102, a CDR-H3 domain comprising or consisting of SEQ ID No: 103, a CDR-L1 domain comprising or consisting of SEQ ID No: 104, a CDR-L2 domain comprising or consisting of SEQ ID No: 105, and a CDR-L3 domain comprising or consisting of SEQ ID No: 106.

[0220] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 107 and a light chain variable region comprising or consisting of SEQ ID No: 108.

[0221] H2_T57H_L2

[0222] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T57H_L2.

[0223] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 109, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 110, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 111, or a variant or fragment thereof.

[0224] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 109, a CDR-H2 domain comprising or consisting of SEQ ID No: 110, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 111. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 109, a CDR-H2 domain comprising or consisting of SEQ ID No: 110, and a CDR-H3 domain comprising or consisting of SEQ ID No: 111.

[0225] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 115 or a variant or fragment thereof.

[0226] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 112, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 113, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 114, or a variant or fragment thereof.

[0227] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 112, a CDR-L2 domain comprising or consisting of SEQ ID No: 113, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 114. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 112, a CDR-L2 domain comprising or consisting of SEQ ID No: 113, and a CDR-L3 domain comprising or consisting of SEQ ID No: 114.

[0228] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 116, or a variant or fragment thereof.

[0229] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0230] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 109, a CDR-H2 domain comprising or consisting of SEQ ID No: 110, a CDR-H3 domain comprising or consisting of SEQ ID No: 111, a CDR-L1 domain comprising or consisting of SEQ ID No: 112, a CDR-L2 domain comprising or consisting of SEQ ID No: 113, and a CDR-L3 domain comprising or consisting of SEQ ID No: 114.

[0231] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 115 and a light chain variable region comprising or consisting of SEQ ID No: 116.

[0232] H2_Y60K_L2

[0233] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_Y60K_L2.

[0234] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 117, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 118, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 119, or a variant or fragment thereof.

[0235] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 117, a CDR-H2 domain comprising or consisting of SEQ ID No: 118, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 119. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 117, a CDR-H2 domain comprising or consisting of SEQ ID No: 118, and a CDR-H3 domain comprising or consisting of SEQ ID No: 119.

[0236] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 123, or a variant or fragment thereof.

[0237] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 120, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 121, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 122, or a variant or fragment thereof.

[0238] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 120, a CDR-L2 domain comprising or consisting of SEQ ID No: 121, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 122. Preferably, however, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 120, a CDR-L2 domain comprising or consisting of SEQ ID No: 121, and a CDR-L3 domain comprising or consisting of SEQ ID No: 122.

[0239] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 124, or a variant or fragment thereof.

[0240] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0241] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 117, a CDR-H2 domain comprising or consisting of SEQ ID No: 118, a CDR-H3 domain comprising or consisting of SEQ ID No: 119, a CDR-L1 domain comprising or consisting of SEQ ID No: 120, a CDR-L2 domain comprising or consisting of SEQ ID No: 121, and a CDR-L3 domain comprising or consisting of SEQ ID No: 122.

[0242] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 123 and a light chain variable region comprising or consisting of SEQ ID No: 124.

[0243] H2_T63Y_L2

[0244] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T63Y_L2.

[0245] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 125, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 126, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 127, or a variant or fragment thereof.

[0246] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 125, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 127. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 125, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, and a CDR-H3 domain comprising or consisting of SEQ ID No: 127.

[0247] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 131, or a variant or fragment thereof.

[0248] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 128, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 129, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 130, or a variant or fragment thereof.

[0249] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 128, a CDR-L2 domain comprising or consisting of SEQ ID No: 129, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 130. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 128, a CDR-L2 domain comprising or consisting of SEQ ID No: 129, and a CDR-L3 domain comprising or consisting of SEQ ID No: 130.

[0250] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 132, or a variant or fragment thereof.

[0251] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0252] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 125, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, a CDR-H3 domain comprising or consisting of SEQ ID No: 127, a CDR-L1 domain comprising or consisting of SEQ ID No: 128, a CDR-L2 domain comprising or consisting of SEQ ID No: 129, and a CDR-L3 domain comprising or consisting of SEQ ID No: 130.

[0253] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 131 and a light chain variable region comprising or consisting of SEQ ID No: 132.

[0254] H3_M105P_VL-par

[0255] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_M105P_VL-par.

[0256] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 133, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 134, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 135, or a variant or fragment thereof.

[0257] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 133, a CDR-H2 domain comprising or consisting of SEQ ID No: 134, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 135. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 133, a CDR-H2 domain comprising or consisting of SEQ ID No: 134, and a CDR-H3 domain comprising or consisting of SEQ ID No: 135.

[0258] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 139 or a variant or fragment thereof.

[0259] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 136, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 137, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 138, or a variant or fragment thereof.

[0260] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 136, a CDR-L2 domain comprising or consisting of SEQ ID No: 137, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 138. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 136, a CDR-L2 domain comprising or consisting of SEQ ID No: 137, and a CDR-L3 domain comprising or consisting of SEQ ID No: 138.

[0261] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 140, or a variant or fragment thereof.

[0262] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0263] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 133, a CDR-H2 domain comprising or consisting of SEQ ID No: 134, a CDR-H3 domain comprising or consisting of SEQ ID No: 135, a CDR-L1 domain comprising or consisting of SEQ ID No: 136, a CDR-L2 domain comprising or consisting of SEQ ID No: 137, and a CDR-L3 domain comprising or consisting of SEQ ID No: 138.

[0264] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 139 and a light chain variable region comprising or consisting of SEQ ID No: 140.

[0265] H2_K65P_L2

[0266] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_K65P_L2.

[0267] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 141, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 142, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 143, or a variant or fragment thereof.

[0268] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 143. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, and a CDR-H3 domain comprising or consisting of SEQ ID No: 143.

[0269] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 147, or a variant or fragment thereof.

[0270] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 144, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 145, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 146, or a variant or fragment thereof.

[0271] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 144, a CDR-L2 domain comprising or consisting of SEQ ID No: 145, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 146. Preferably, however, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 144, a CDR-L2 domain comprising or consisting of SEQ ID No: 145, and a CDR-L3 domain comprising or consisting of SEQ ID No: 146.

[0272] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 148, or a variant or fragment thereof.

[0273] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0274] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, a CDR-H3 domain comprising or consisting of SEQ ID No: 143, a CDR-L1 domain comprising or consisting of SEQ ID No: 144, a CDR-L2 domain comprising or consisting of SEQ ID No: 145, and a CDR-L3 domain comprising or consisting of SEQ ID No: 146.

[0275] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 147 and a light chain variable region comprising or consisting of SEQ ID No: 148.

[0276] H2_G66Q_L2

[0277] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_G66Q_L2.

[0278] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 149, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 150, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 151, or a variant or fragment thereof.

[0279] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 149, a CDR-H2 domain comprising or consisting of SEQ ID No: 150, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 151. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 149, a CDR-H2 domain comprising or consisting of SEQ ID No: 150, and a CDR-H3 domain comprising or consisting of SEQ ID No: 151.

[0280] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 155, or a variant or fragment thereof.

[0281] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 152, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 153, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 154, or a variant or fragment thereof.

[0282] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 152, a CDR-L2 domain comprising or consisting of SEQ ID No: 153, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 154. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 152, a CDR-L2 domain comprising or consisting of SEQ ID No: 153, and a CDR-L3 domain comprising or consisting of SEQ ID No: 154.

[0283] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 156, or a variant or fragment thereof.

[0284] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0285] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 149, a CDR-H2 domain comprising or consisting of SEQ ID No: 150, a CDR-H3 domain comprising or consisting of SEQ ID No: 151, a CDR-L1 domain comprising or consisting of SEQ ID No: 152, a CDR-L2 domain comprising or consisting of SEQ ID No: 153, and a CDR-L3 domain comprising or consisting of SEQ ID No: 154.

[0286] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 155 and a light chain variable region comprising or consisting of SEQ ID No: 156.

[0287] H3_M105P_L2

[0288] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H3_M105P_L2.

[0289] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 157, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 158, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 159, or a variant or fragment thereof.

[0290] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 157, a CDR-H2 domain comprising or consisting of SEQ ID No: 158, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 159. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 157, a CDR-H2 domain comprising or consisting of SEQ ID No: 158, and a CDR-H3 domain comprising or consisting of SEQ ID No: 159.

[0291] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 163, or a variant or fragment thereof.

[0292] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 160, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 161, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 162, or a variant or fragment thereof.

[0293] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 160, a CDR-L2 domain comprising or consisting of SEQ ID No: 161, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 162. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 160, a CDR-L2 domain comprising or consisting of SEQ ID No: 161, and a CDR-L3 domain comprising or consisting of SEQ ID No: 162.

[0294] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 164, or a variant or fragment thereof.

[0295] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0296] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 157, a CDR-H2 domain comprising or consisting of SEQ ID No: 158, a CDR-H3 domain comprising or consisting of SEQ ID No: 159, a CDR-L1 domain comprising or consisting of SEQ ID No: 160, a CDR-L2 domain comprising or consisting of SEQ ID No: 161, and a CDR-L3 domain comprising or consisting of SEQ ID No: 162.

[0297] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 163 and a light chain variable region comprising or consisting of SEQ ID No: 164.

[0298] 51B12_VH_L2

[0299] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as 51B12_VH_L2.

[0300] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 165, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 166, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 167, or a variant or fragment thereof.

[0301] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 165, a CDR-H2 domain comprising or consisting of SEQ ID No: 166, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 167. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 165, a CDR-H2 domain comprising or consisting of SEQ ID No: 166, and a CDR-H3 domain comprising or consisting of SEQ ID No: 167.

[0302] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 171, or a variant or fragment thereof.

[0303] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 168, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 169, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 170, or a variant or fragment thereof.

[0304] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 168, a CDR-L2 domain comprising or consisting of SEQ ID No: 169, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 170. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 168, a CDR-L2 domain comprising or consisting of SEQ ID No: 169, and a CDR-L3 domain comprising or consisting of SEQ ID No: 170.

[0305] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 172, or a variant or fragment thereof.

[0306] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0307] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 165, a CDR-H2 domain comprising or consisting of SEQ ID No: 166, a CDR-H3 domain comprising or consisting of SEQ ID No: 167, a CDR-L1 domain comprising or consisting of SEQ ID No: 168, a CDR-L2 domain comprising or consisting of SEQ ID No: 169, and a CDR-L3 domain comprising or consisting of SEQ ID No: 170.

[0308] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 171 and a light chain variable region comprising or consisting of SEQ ID No: 172.

[0309] H2_T56H_VL-par

[0310] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T56H_VL-par.

[0311] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 173, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 174, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 175, or a variant or fragment thereof.

[0312] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 173, a CDR-H2 domain comprising or consisting of SEQ ID No: 174, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 175. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 173, a CDR-H2 domain comprising or consisting of SEQ ID No: 174, and a CDR-H3 domain comprising or consisting of SEQ ID No: 175.

[0313] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 179, or a variant or fragment thereof.

[0314] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 176, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 177, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 178, or a variant or fragment thereof.

[0315] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 176, a CDR-L2 domain comprising or consisting of SEQ ID No: 177, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 178. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 176, a CDR-L2 domain comprising or consisting of SEQ ID No: 177, and a CDR-L3 domain comprising or consisting of SEQ ID No: 178.

[0316] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 180, or a variant or fragment thereof.

[0317] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0318] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 173, a CDR-H2 domain comprising or consisting of SEQ ID No: 174, a CDR-H3 domain comprising or consisting of SEQ ID No: 175, a CDR-L1 domain comprising or consisting of SEQ ID No: 176, a CDR-L2 domain comprising or consisting of SEQ ID No: 177, and a CDR-L3 domain comprising or consisting of SEQ ID No: 178.

[0319] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 179 and a light chain variable region comprising or consisting of SEQ ID No: 180.

[0320] H2_T57H_VL-par

[0321] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T57H_VL-par.

[0322] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 181, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 182, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 183, or a variant or fragment thereof.

[0323] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 181, a CDR-H2 domain comprising or consisting of SEQ ID No: 182, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 183. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 181, a CDR-H2 domain comprising or consisting of SEQ ID No: 182, and a CDR-H3 domain comprising or consisting of SEQ ID No: 183.

[0324] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 187, or a variant or fragment thereof.

[0325] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 184, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 185, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 186, or a variant or fragment thereof.

[0326] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 184, a CDR-L2 domain comprising or consisting of SEQ ID No: 185, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 186. Preferably, however, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 184, a CDR-L2 domain comprising or consisting of SEQ ID No: 185, and a CDR-L3 domain comprising or consisting of SEQ ID No: 186.

[0327] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 188, or a variant or fragment thereof.

[0328] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0329] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 181, a CDR-H2 domain comprising or consisting of SEQ ID No: 182, a CDR-H3 domain comprising or consisting of SEQ ID No: 183, a CDR-L1 domain comprising or consisting of SEQ ID No: 184, a CDR-L2 domain comprising or consisting of SEQ ID No: 185, and a CDR-L3 domain comprising or consisting of SEQ ID No: 186.

[0330] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 187 and a light chain variable region comprising or consisting of SEQ ID No: 188.

[0331] H2_Y60K_VL-par

[0332] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_Y60K_VL-par.

[0333] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 189, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 190, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 191, or a variant or fragment thereof.

[0334] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 189, a CDR-H2 domain comprising or consisting of SEQ ID No: 190, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 191. Preferably, however, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 189, a CDR-H2 domain comprising or consisting of SEQ ID No: 190, and a CDR-H3 domain comprising or consisting of SEQ ID No: 191.

[0335] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence substantially set forth in SEQ ID No: 195, or a variant or fragment thereof.

[0336] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 192, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 193, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 194, or a variant or fragment thereof.

[0337] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 192, a CDR-L2 domain comprising or consisting of SEQ ID No: 193, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 194. Preferably, however, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 192, a CDR-L2 domain comprising or consisting of SEQ ID No: 193, and a CDR-L3 domain comprising or consisting of SEQ ID No: 194.

[0338] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 196, or a variant or fragment thereof.

[0339] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0340] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 189, a CDR-H2 domain comprising or consisting of SEQ ID No: 190, a CDR-H3 domain comprising or consisting of SEQ ID No: 191, a CDR-L1 domain comprising or consisting of SEQ ID No: 192, a CDR-L2 domain comprising or consisting of SEQ ID No: 193, and a CDR-L3 domain comprising or consisting of SEQ ID No: 194.

[0341] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 195 and a light chain variable region comprising or consisting of SEQ ID No: 196.

[0342] H2_T63Y_VL-par

[0343] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_T63Y_VL-par.

[0344] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 197, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 198, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 199, or a variant or fragment thereof.

[0345] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 197, a CDR-H2 domain comprising SEQ ID No: 198, and / or a CDR-H3 domain comprising SEQ ID No: 199. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising SEQ ID No: 197, a CDR-H2 domain comprising SEQ ID No: 198, and a CDR-H3 domain comprising SEQ ID No: 199.

[0346] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 203, or a variant or fragment thereof.

[0347] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 200, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 201, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 202, or a variant or fragment thereof.

[0348] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 200, a CDR-L2 domain comprising or consisting of SEQ ID No: 201, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 202. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 200, a CDR-L2 domain comprising or consisting of SEQ ID No: 201, and a CDR-L3 domain comprising or consisting of SEQ ID No: 202.

[0349] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 204, or a variant or fragment thereof.

[0350] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0351] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 197, a CDR-H2 domain comprising or consisting of SEQ ID No: 198, a CDR-H3 domain comprising or consisting of SEQ ID No: 199, a CDR-L1 domain comprising or consisting of SEQ ID No: 200, a CDR-L2 domain comprising or consisting of SEQ ID No: 201, and a CDR-L3 domain comprising or consisting of SEQ ID No: 202.

[0352] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 203 and a light chain variable region comprising or consisting of SEQ ID No: 204.

[0353] H2_K65P_VL-par

[0354] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_K65P_VL-par.

[0355] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 205, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 206, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 207, or a variant or fragment thereof.

[0356] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 205, a CDR-H2 domain comprising or consisting of SEQ ID No: 206, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 207. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 205, a CDR-H2 domain comprising or consisting of SEQ ID No: 206, and a CDR-H3 domain comprising or consisting of SEQ ID No: 207.

[0357] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 211, or a variant or fragment thereof.

[0358] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 208, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 209, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 210, or a variant or fragment thereof.

[0359] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 208, a CDR-L2 domain comprising or consisting of SEQ ID No: 209, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 210. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 208, a CDR-L2 domain comprising or consisting of SEQ ID No: 209, and a CDR-L3 domain comprising or consisting of SEQ ID No: 210.

[0360] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 212, or a variant or fragment thereof.

[0361] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0362] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 205, a CDR-H2 domain comprising or consisting of SEQ ID No: 206, a CDR-H3 domain comprising or consisting of SEQ ID No: 207, a CDR-L1 domain comprising or consisting of SEQ ID No: 208, a CDR-L2 domain comprising or consisting of SEQ ID No: 209, and a CDR-L3 domain comprising or consisting of SEQ ID No: 210.

[0363] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 211 and a light chain variable region comprising or consisting of SEQ ID No: 212.

[0364] H2_G66Q_VL-par

[0365] In one embodiment, the antibody or antigen-binding fragment thereof is referred to therein as H2_G66Q_VL-par.

[0366] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 213, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H2 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 214, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-H3 domain comprising or consisting of a sequence substantially set forth in SEQ ID No: 215, or a variant or fragment thereof.

[0367] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 213, a CDR-H2 domain comprising or consisting of SEQ ID No: 214, and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 215. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 213, a CDR-H2 domain comprising or consisting of SEQ ID No: 214, and a CDR-H3 domain comprising or consisting of SEQ ID No: 215.

[0368] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 219, or a variant or fragment thereof.

[0369] Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L1 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 216, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L2 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 217, or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof comprises a CDR-L3 domain comprising, or consisting of, a sequence substantially set forth in SEQ ID No: 218, or a variant or fragment thereof.

[0370] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 216, a CDR-L2 domain comprising or consisting of SEQ ID No: 217, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 218. Preferably, however, the antibody or antigen-binding fragment thereof comprises: a CDR-L1 domain comprising or consisting of SEQ ID No: 216, a CDR-L2 domain comprising or consisting of SEQ ID No: 217, and a CDR-L3 domain comprising or consisting of SEQ ID No: 218.

[0371] Preferably, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising, or consisting of, the sequence substantially set forth in SEQ ID No: 220, or a variant or fragment thereof.

[0372] Preferably, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five or at least six CDRs. Preferably, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.

[0373] Preferably, the antibody or antigen-binding fragment thereof comprises: a CDR-H1 domain comprising or consisting of SEQ ID No: 213, a CDR-H2 domain comprising or consisting of SEQ ID No: 214, a CDR-H3 domain comprising or consisting of SEQ ID No: 215, a CDR-L1 domain comprising or consisting of SEQ ID No: 216, a CDR-L2 domain comprising or consisting of SEQ ID No: 217, and a CDR-L3 domain comprising or consisting of SEQ ID No: 218.

[0374] Preferably, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising or consisting of SEQ ID No: 219 and a light chain variable region comprising or consisting of SEQ ID No: 220.

[0375] In a second aspect of the present invention, an antibody or an antigen-binding fragment thereof is provided, wherein the antibody or the antigen-binding fragment thereof specifically binds to ZIP12 and comprises six CDR sequences, such as Figure 9b Indicated for each antibody.

[0376] For example, in one embodiment, the antibody or antigen-binding fragment thereof preferably includes the six CDR sequences described for the antibody referred to as "H3_W99H_L1", such as Figure 9b As shown, CDR-H1=SEQ ID No:13; CDR-H2=SEQ ID No:14; CDR-H3=SEQ ID No:15; CDR-L1=SEQ ID No:16; CDR-L2=SEQ ID No:17; CDR-L3=SEQ ID No:18. Figure 9b The same is true for each of the other antibody CDR sequences shown.

[0377] In addition, the antibody or antigen-binding fragment thereof preferably includes Figure 9b For example, in one embodiment, the antibody or antigen-binding fragment thereof preferably comprises a VH / VL sequence for an antibody cloned as "H3_W99H_L1", such as Figure 9b As shown, VH = SEQ ID No: 19; VL = SEQ ID No: 20. Figure 9b The same is true for the VH / VL sequences of each of the other antibodies shown.

[0378] like Figure 9a As shown in the antibody clone referred to as "51B12 parent", the antibody or antigen-binding fragment thereof of the present invention may not include six CDR sequences (or VH / VL sequences).

[0379] The antibody or antigen-binding fragment thereof of the second aspect specifically binds to the extracellular domain of ZIP12 and recognizes an epitope consisting of ADLLQVLSAGDHPPHNHSRS (SEQ ID No: 252) or a variant or fragment thereof. Preferably, the antibody or antigen-binding fragment thereof of the second aspect specifically binds to the extracellular domain of ZIP12 and recognizes an epitope consisting of LLQVLSAGDHPPHNHSRS (SEQ ID No: 1) or a variant or fragment thereof. The epitope of the antibody or antigen-binding fragment thereof may be as defined in the first aspect.

[0380] Advantageously, the anti-ZIP12 activity of the antibodies or antigen-binding fragments thereof according to the first and second aspects of the invention means that they themselves have utility as therapeutic agents and can be used to treat, ameliorate or prevent hypoxia-induced or hypoxia-related disorders, particularly pulmonary hypertension.

[0381] Accordingly, in a third aspect of the invention, there is provided a use of the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect in therapy.

[0382] In a fourth aspect of the present invention, provided is the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect for use in treating, preventing or ameliorating a hypoxia-related disorder.

[0383] According to the fifth aspect of the present invention, there is provided a method for treating, preventing or ameliorating a hypoxia-related disorder in a subject, the method comprising administering or having administered a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect to a patient in need of such treatment.

[0384] The hypoxia-related disorder may be selected from the group consisting of ischemia-reperfusion injury (IRI), cardiovascular disease, ischemic heart disease, ischemic brain disease, macular degeneration, ocular ischemic syndrome, ischemic optic neuropathy (ION), diabetic retinopathy, arthritis, inflammation, sepsis, sepsis-induced shock, kidney disease, tissue fibrosis, gastrointestinal disease, neurodegenerative disease, respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary hypertension, hypoxic pulmonary hypertension, severe pulmonary hypertension, COPD, idiopathic pulmonary fibrosis (IPF), diabetic retinopathy, diabetes, corneal neovascularization, pathogenic angiogenesis, cancer and musculoskeletal disease.

[0385] The inventors have demonstrated that the hypoxic core of a tumor is the site of hypoxia-stimulated neovascularization (Zhao et al., 2015, The zinc transporter, ZIP12, regulates the pulmonary vascular response to chronic hypoxia, Nature, Vol: 524, ISSN: 0028-0836, Pages: 356-360), and hypoxia is considered a universal hallmark of tumors and leads to resistance to radiation and chemotherapy. Therefore, ZIP12 has been shown by the inventors to be upregulated under hypoxic conditions and is a key factor in disease progression, and has been identified by the inventors as an ideal therapeutic target for cancer. Inhibition of ZIP12 in the tumor microenvironment may limit the blood supply to the tumor, thereby limiting tumor growth and / or inducing hypoxic tumor cell death.

[0386] Thus, in one embodiment, the hypoxia-related disorder is cancer.

[0387] Preferably, the use or method for treating, preventing or ameliorating cancer comprises inhibiting angiogenesis. Preferably, the use or method comprises restricting the blood supply to the tumor.

[0388] Preferably however, the hypoxia-related disorder is pulmonary hypertension.Most preferably, the hypoxia-related disorder is hypoxic pulmonary hypertension.

[0389] It should be understood that the antibodies or antigen-binding fragments thereof according to the present invention (collectively referred to herein as "preparations") can be used for monotherapy (e.g., using the antibodies or antigen-binding fragments thereof alone) for treating, improving or preventing hypoxia-related disorders, preferably pulmonary hypertension. Alternatively, the preparations according to the present invention can be used as an adjuvant therapy or in combination with known therapies (known therapeutics) for treating, improving or preventing hypoxia-related disorders (preferably pulmonary hypertension), such known therapies, for example: anticoagulants, such as warfarin, diuretics, digoxin; endothelin receptor antagonists, such as bosentan, ambrisentan and macitentan; phosphodiesterase 5 inhibitors, such as sildenafil These include sildenafil and tadalafil; prostaglandins, such as epoprostenol, iloprost, and treprostinil; soluble guanylate cyclase stimulators, such as riociguat; and the calcium channel blockers nifedipine, diltiazem, nicardipine, and amlodipine.

[0390] The preparation according to the present invention can be combined into a composition with a variety of different forms, depending on the use mode of the composition. Therefore, for example, the composition can be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension or any other suitable form, which can be taken by a person or animal in need of treatment. It should be understood that the drug carrier according to the present invention should be a carrier that can be well tolerated by the subject to which it is given.

[0391] The medicaments comprising the formulations of the present invention can be used in a variety of ways. For example, oral administration may be desired, in which case the formulation can be contained in a composition that can be taken orally, for example, in the form of tablets, capsules, or liquids. The composition comprising the formulations of the present invention and the medicament can be administered by inhalation (e.g., intranasally). The composition can also be formulated for topical use. For example, a cream or ointment can be applied to the skin.

[0392] Medicament and medicine according to the present invention can also be combined in slow release or delayed release device.For example, this device can be inserted on or under the skin, and medicine can be released in a few weeks or even months.This device can be located at least adjacent to the position of the treatment site.When needing to carry out long-term treatment with the medicament used according to the present invention and usually needing frequent administration (for example, at least daily injection), this device may be particularly advantageous.

[0393] In a preferred embodiment, the agents and medicaments according to the present invention can be administered to a subject by injection into the bloodstream or directly into the site in need of treatment. The injection can be intravenous (bolus or infusion) or subcutaneous (bolus or infusion).

[0394] It should be understood that the amount of antibodies and fragments (i.e., preparations) required depends on their biological activity and bioavailability, which in turn depends on the mode of administration, the physicochemical properties of the preparation, and whether it is used as a monotherapy or for combination therapy. The frequency of administration will also be affected by the half-life of the agent in the subject. The optimal dose for administration can be determined by those skilled in the art and will vary with the specific agent used, the strength of the pharmaceutical composition, the mode of administration, and the progression of pulmonary hypertension. Other factors depending on the specific subject being treated will result in the need to adjust the dose, including subject age, weight, sex, diet, and administration time.

[0395] In general, the daily dose of the medicament of the present invention can be used to treat, improve or prevent diseases such as pulmonary hypertension between 0.01 μg / kg body weight and 100 mg / kg body weight, and the specific daily dose depends on which preparation is used. More preferably, the daily dose of the preparation is between 1 μg / kg body weight and 100 mg / kg body weight, more preferably between 10 μg / kg and 10 mg / kg body weight, and most preferably between about 100 μg / kg and 10 mg / kg body weight.

[0396] The preparation can be administered before, during or after the onset of pulmonary hypertension. The daily dose can be administered as a single dose (e.g., once daily injection). Alternatively, the preparation may need to be administered twice or more in one day. For example, the preparation can be administered twice (or more times, depending on the severity of the pulmonary hypertension being treated), with a daily dose of 0.07 μg and 700 mg (i.e., assuming a body weight of 70 kg). The patient receiving treatment can take the first dose upon waking up, and then take the second dose at night (if it is a two-dose regimen), or take it every 3 or 4 hours thereafter. Alternatively, a sustained-release device can be used to provide the patient with an optimal dose of the medicament of the present invention without the need for repeated doses. Known procedures, such as procedures routinely used in the pharmaceutical industry (e.g., in vivo experiments, clinical trials, etc.), can be used to form specific preparations and precise treatment regimens (e.g., daily doses and dosing frequency of the preparation) of the preparation of the present invention.

[0397] In a sixth aspect of the present invention, a pharmaceutical composition is provided, comprising the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect, and optionally a pharmaceutically acceptable carrier.

[0398] The pharmaceutical composition is preferably an antihypertensive drug, that is, a pharmaceutical preparation for therapeutically improving, preventing or treating pulmonary hypertension.

[0399] The present invention also provides in a seventh aspect a method for preparing the pharmaceutical composition according to the sixth aspect, the method comprising combining a therapeutically effective amount of the antibody or antigen-binding fragment thereof of the first aspect or the second aspect with a pharmaceutically acceptable carrier.

[0400] The antibody or antigen-binding fragment thereof may be as defined in relation to the first aspect or the second aspect.

[0401] The "subject" may be a vertebrate, a mammal or a domestic animal. Thus, the medicament according to the invention may be used to treat any mammal, such as livestock (e.g., a horse), a pet, or may be used in other veterinary applications. Most preferably, the subject is a human.

[0402] A "therapeutically effective amount" of an antibody or antigen-binding fragment thereof is any amount that, when administered to a subject, is the dose required to treat pulmonary hypertension or produce a desired effect.

[0403] For example, the therapeutically effective amount of the antibody or fragment thereof used can be about 0.1 ng / kg to about 100 mg / kg, preferably about 1 ng / kg to about 10 mg / kg. Preferably, the amount of the antibody or fragment is about 10 ng / kg to about 10 mg / kg, most preferably about 50 ng / kg to about 5 mg / kg.

[0404] The "pharmaceutically acceptable carrier" referred to herein is any known compound or combination of known compounds known to those skilled in the art that can be used to formulate a pharmaceutical composition.

[0405] In one embodiment, the pharmaceutically acceptable carrier can be a solid, and the composition can be in the form of a powder or tablet. A solid pharmaceutically acceptable carrier can include one or more substances that can also be used as a flavoring agent, lubricant, solubilizer, suspending agent, dye, filler, tackifier, compression aid, inert binder, sweetener, preservative, dye, coating or tablet disintegrant. The carrier can also be an encapsulating material. In a powder, the carrier is a finely divided solid mixed with the finely divided active agent of the present invention. In a tablet, the active agent can be mixed with a carrier having the necessary compression properties in an appropriate proportion and compacted in the desired shape and size. Powders and tablets preferably contain up to 99% of the active agent. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugar, lactose, dextrin, starch, gelatin, cellulose, polyvinyl pyrrolidine, low melting point wax and ion exchange resin. In another embodiment, the drug carrier can be a gel, and the composition can be in the form of a cream or the like.

[0406] However, the pharmaceutical carrier can be a liquid, and the pharmaceutical composition is in the form of a solution. Liquid carriers are used to prepare solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The activating agent of the present invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier, such as water, an organic solvent, a mixture of the two or a pharmaceutically acceptable oil or fat. The liquid carrier can include other suitable pharmaceutical additives, such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickeners, colorants, viscosity modifiers, stabilizers or osmotic regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as described above, such as cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohol (including monohydric alcohols and polyols, such as glycols) and derivatives thereof, and oils (such as fractionated coconut oil and peanut oil). For parenteral administration, the carrier can also be an oily ester, such as ethyl oleate and isopropyl myristate. Sterile liquid carriers can be used for sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

[0407] Liquid pharmaceutical compositions as sterile solutions or suspensions can be used, for example, by intramuscular injection, intrathecal injection, epidural injection, intraperitoneal injection, intravenous injection, particularly subcutaneous injection. The medicament can be prepared as a sterile solid composition, which can be dissolved or suspended using sterile water, saline or other suitable sterile injectable media when administered.

[0408] The preparations and compositions of the present invention can be taken orally in the form of sterile solutions or suspensions, containing other solutes or suspending agents (e.g., sufficient saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitol monooleate, polysorbate 80 (oleate copolymerized with sorbitol and its anhydride and ethylene oxide), etc. The preparations used according to the present invention can also be taken orally in the form of liquid or solid compositions. Compositions suitable for oral administration include solid forms such as pills, capsules, granules, tablets and powders; and liquid forms such as solutions, syrups, elixirs and suspensions. Forms suitable for parenteral administration include sterile solutions, emulsions and suspensions.

[0409] The invention also extends to methods of making the antibodies of the first or second aspects, and the antibodies so produced.

[0410] In an eighth aspect, there is provided an antibody or antigen-binding fragment thereof obtained by the following method:

[0411] (i) immunizing a host organism with an extracellular epitope of ZIP12, wherein the extracellular epitope of ZIP12 comprises or consists of SEQ ID No: 252 or SEQ ID No: 1 or a variant or fragment thereof; and

[0412] (ii) collecting the antibody or antigen-binding fragment thereof from the host.

[0413] The host may be a mammal, and may be a human, a rabbit, or a mouse.

[0414] The epitope may be linear or conformational. The epitope may be denatured or folded. However, preferably, a folded epitope is used to immunize the host.

[0415] Preferably, the method comprises bleeding the host animal and then collecting the antibody or antigen binding fragment thereof preferably from the blood, most preferably serum. Preferably, the serum is passed through a gravity column having a covalently bound peptide carrier. After washing, the antibody or antigen binding fragment thereof is preferably eluted in a buffer, preferably an acidic buffer, and the solution may then be neutralized. The method may further comprise dialyzing a suitable buffer (e.g., PBS) and optionally lyophilizing.

[0416] In the ninth aspect of the present invention, a polynucleotide sequence encoding the antibody or antigen-binding fragment thereof defined in the first aspect or the second aspect is provided.

[0417] In a tenth aspect of the present invention, an expression cassette is provided, comprising the polynucleotide sequence according to the ninth aspect.

[0418] The polynucleotide sequence encoding the antibody or antigen-binding fragment of the present invention is preferably contained in a recombinant vector, such as a recombinant vector for delivery into a target host cell to produce the antibody or antigen-binding fragment thereof.

[0419] Accordingly, in an eleventh aspect of the present invention, there is provided a recombinant vector comprising the expression cassette according to the tenth aspect.

[0420] The vector encoding the antibody or its Fab of the first aspect or the second aspect can be, for example, a plasmid, a cosmid or a phage and / or a viral vector. Such recombinant vectors are very useful in the delivery system of the present invention for transforming cells with nucleotide sequences. The nucleotide sequence can preferably be a DNA sequence, and it is this DNA sequence encoding that forms the antibody or its Fab of the first aspect.

[0421] The recombinant vector encoding the antibody or its antigen-binding fragment of the first aspect or the second aspect may also include other functional elements. For example, they may further include a variety of other functional elements, including a suitable promoter for starting transgenic expression after the vector is introduced into the host cell. For example, the vector is preferably capable of autonomous replication in the nucleus of the host cell. In this case, an element that may be required to induce or regulate DNA replication may be required in the recombinant vector. Alternatively, the recombinant vector may be designed so that it is integrated into the genome of the host cell. In this case, it is envisioned that the DNA sequence (for example, by homologous recombination) that is conducive to targeted integration is envisioned. Suitable promoters may include SV40 promoters, CMV, EF1a, PGK, viral long terminal repeats, and inducible promoters, as examples, such as tetracycline induction systems. The box or vector may also include a terminator, such as β-globin, SV40 polyadenylation sequence, or a synthetic polyadenylation sequence. The recombinant vector may also include a promoter or a regulator or an enhancer to control the expression of nucleic acid as required.

[0422] The vector may also include DNA encoding a gene that can be used as a selectable marker in the cloning process, i.e., cells that have been transfected or transformed can be selected, and cells that carry a vector incorporating heterologous DNA can be selected. For example, it is envisioned that ampicillin, neomycin, puromycin or chloramphenicol are resistant. In addition, the selectable marker gene can be in a different vector used simultaneously with a vector containing a transgenic gene. The box or vector may also include DNA that is related to regulating the expression of a nucleotide sequence or for targeting a certain portion of the expressed polypeptide to a host cell.

[0423] The purified vector can be directly inserted into the host cell by appropriate means, such as direct endocytosis. The vector can be directly introduced into the host cell (e.g., eukaryotic or prokaryotic cell) by transfection, infection, electroporation, microinjection, cell fusion, protoplast fusion, calcium phosphate, cationic lipid-based lipofection, polymer- or dendrimer-based methods, or ballistic bombardment. Alternatively, the vector of the present invention can be directly introduced into the host cell using a particle gun.

[0424] Alternatively, the delivery system can provide the polynucleotide to the host cell without incorporating it into a vector. For example, the nucleic acid molecule can be incorporated into a liposome or a viral particle. Alternatively, a "naked" polynucleotide can be inserted into a host cell by suitable means such as direct endocytic uptake.

[0425] In a twelfth aspect of the present invention, a host cell is provided, comprising the polynucleotide sequence according to the ninth aspect, the expression cassette according to the tenth aspect or the vector according to the eleventh aspect.

[0426] The host cell can be a eukaryotic or prokaryotic host cell. Preferably, the host cell is a eukaryotic host cell. More preferably, the host cell is a mammalian host cell, such as a NS0 mouse myeloma cell, a PER. Human cells, human embryonic kidney 293 cells or Chinese hamster ovary (CHO) cells. Most preferably, the host cell is a CHO cell.

[0427] In the thirteenth aspect, a method for preparing the antibody or antigen-binding fragment thereof of the first aspect or the second aspect is provided, the method comprising:

[0428] a) introducing the recombinant vector of the eleventh aspect into a host cell; and

[0429] b) culturing the host cell under conditions capable of producing the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect.

[0430] The host cell in step a) can be a eukaryotic or prokaryotic host cell. Preferably, the host cell is a eukaryotic host cell. More preferably, the host cell is a mammalian host cell, such as NS0 mouse myeloma cells, PER. Human cells, human embryonic kidney 293 cells or Chinese hamster ovary (CHO) cells. Most preferably, the host cell is a CHO cell.

[0431] The method may further include (c) collecting, centrifuging and / or filtering the cell culture medium to obtain a cell culture supernatant containing the antibody or antigen-binding fragment thereof.

[0432] The method may further comprise (d) isolating and purifying the antibody or antigen-binding fragment thereof from the cell culture supernatant. Preferably, the purification is performed by at least one chromatography step.

[0433] Suitable chromatography steps include affinity chromatography and / or ion exchange chromatography. Preferably, the affinity chromatography is protein A chromatography. The ion exchange chromatography may be anion exchange chromatography and / or cation exchange chromatography.

[0434] Preferably, step (d) comprises isolating and purifying the antibody or antigen-binding fragment thereof from the cell culture supernatant by:

[0435] i) Protein A chromatography;

[0436] ii) anion exchange chromatography; and / or

[0437] iii) Cation exchange chromatography.

[0438] The method may further include (e) filtering the purified antibody or Fab produced by step (d). Preferably, step (e) includes virus filtration. Therefore, it is preferred to use a virus filter to filter the purified antibody or Fab produced by step (d). Suitable membranes are known to those skilled in the art.

[0439] As discussed herein, in remodeled pulmonary arterioles of rats, cows, and humans susceptible to hypoxia-induced pulmonary hypertension, ZIP12 expression is increased in many cell types, including endothelial cells, smooth muscle cells, and interstitial cells. Therefore, given that the antibodies of the present invention are capable of binding to an extracellular epitope of ZIP12 comprising SEQ ID No: 252 and / or SEQ ID No: 1, or a variant or fragment thereof, the antibodies or antigen-binding fragments thereof can be used as a robust diagnostic tool by detecting the presence of ZIP12 and determining its concentration.

[0440] Therefore, in a fourteenth aspect, there is provided use of the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect in diagnosis or prognosis.

[0441] According to a fifteenth aspect of the present invention, there is provided a use of the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect in diagnosing or prognosing a hypoxia-related disease.

[0442] According to a sixteenth aspect, a method for diagnosing or prognosing a hypoxia-related disorder in a subject is provided, the method comprising detecting ZIP12 in a biological sample obtained from the subject using the antibody or antigen-binding fragment thereof according to the first aspect or the second aspect.

[0443] Preferably, the hypoxia-related disorder is selected from the group consisting of ischemia-reperfusion injury (IRI), cardiovascular disease, ischemic heart disease, ischemic brain disorder, macular degeneration, ocular ischemic syndrome, ischemic optic neuropathy (ION), diabetic retinopathy, arthritis, inflammation, sepsis, sepsis-induced shock, kidney disease, tissue fibrosis, gastrointestinal disease, neurodegenerative disease, respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary hypertension, hypoxic pulmonary hypertension, severe pulmonary hypertension, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), diabetic retinopathy, diabetes, corneal neovascularization, pathogenic vascular growth, and musculoskeletal disease.

[0444] Preferably, the hypoxia-related disorder is cancer or pulmonary hypertension.Most preferably, the hypoxia-related disorder is pulmonary hypertension.

[0445] The method may be an in vitro or ex vivo method. Preferably, the method is an in vitro method.

[0446] The above uses and methods may comprise determining the expression level of ZIP12 in a subject, preferably wherein an increased concentration of ZIP12 in a biological sample when compared to a reference concentration from a healthy control population is indicative of pulmonary hypertension or a poor prognosis.

[0447] In one embodiment, the presence of ZIP12 in the lung can be considered an indication of pulmonary hypertension or a poor prognosis. The presence of ZIP12 can be detected by immunocytochemistry.

[0448] In one embodiment, a 1-fold increase in ZIP12 compared to a reference from a healthy control population indicates pulmonary hypertension or a poor prognosis. In one embodiment, a 2-fold, 3-fold, 4-fold or 5-fold increase in ZIP12 compared to a reference from a healthy control population indicates pulmonary hypertension or a poor prognosis. In one embodiment, a 10-fold, 50-fold or 100-fold increase in ZIP12 compared to a reference from a healthy control population indicates pulmonary hypertension or a poor prognosis.

[0449] According to the seventeenth aspect of the present invention, a kit is provided for diagnosing a subject suffering from a hypoxia-related disorder, or for providing a prognosis of a subject's disorder, the kit comprising an antibody or an antigen-binding fragment thereof according to the first aspect or the second aspect, for detecting ZIP12 in a sample from the subject.

[0450] The kit may further include instructions for use and / or a container for obtaining a biological sample from a subject.

[0451] Preferably, the hypoxia-related disorder is as defined herein, and is preferably pulmonary hypertension.

[0452] Prognosis may be related to determining the treatment outcome of a subject diagnosed with pulmonary hypertension. Prognosis may involve predicting the rate and / or duration of progression or improvement of pulmonary hypertension in a subject, the probability of survival, and / or the efficacy of various treatment regimens. Thus, a poor prognosis may indicate progression of pulmonary hypertension, a low probability of survival, and a reduced efficacy of the treatment regimen. A good prognosis may indicate relief of pulmonary hypertension, an improved survival rate, and an improved efficacy of the treatment regimen.

[0453] Preferably, the sample comprises a biological sample.The sample may be any material obtainable from a subject from which protein can be obtained.

[0454] The biological sample can be a tissue or a biological fluid. The biological sample can be any material obtained from a subject from which endothelial cells, smooth muscle cells and / or interstitial cells can be obtained. In addition, the sample can be blood, plasma, serum, spinal fluid, urine, sweat, saliva, tears, breast aspirate, breast milk, prostatic fluid, semen, vaginal fluid, feces, cervical scraping, cells, amniotic fluid, intraocular fluid, mucus, breath water, animal tissue, cell lysate, tumor tissue, hair, skin, cheek scraping, lymph, interstitial fluid, nail, bone marrow, cartilage, prion, bone meal, ear wax, lymph, granuloma, cancer biopsy or a combination thereof.

[0455] The sample can be a fluid aspirate. For example, the sample can be bronchoalveolar lavage (BAL), ascites, pleural lavage, or pericardial lavage.

[0456] The sample may comprise blood, urine, tissue, etc. In a preferred embodiment, the biological sample comprises a blood sample. The blood may be venous or arterial blood. The blood sample may be assayed immediately. Alternatively, the blood sample may be stored at low temperatures, such as in a refrigerator, or even frozen before the method is performed. Alternatively, the blood sample may be stored at room temperature, such as between 18°C ​​and 22°C, before the method is performed. The blood sample may comprise serum. The blood sample may comprise plasma. However, preferably, the detection is performed on whole blood, and most preferably the blood sample is peripheral blood.

[0457] Before contacting with the antibodies of the invention, the blood may be further processed. For example, an anticoagulant may be added, such as citrate (e.g., sodium citrate), hirudin, heparin, PPACK or sodium fluoride. Thus, the sample collection container may contain an anticoagulant to prevent the blood sample from clotting.

[0458] Preferably, the sample may comprise endothelial cells, smooth muscle cells and / or interstitial cells, preferably lung endothelial cells, smooth muscle cells and / or interstitial cells.

[0459] It should be understood that the present invention extends to any nucleic acid or peptide or variant, derivative or analog thereof, which substantially comprises the amino acid or nucleic acid sequence of any of the sequences described herein, including variants or fragments thereof. The terms "substantially the amino acid / nucleotide / peptide sequence", "variant" and "fragment" may be a sequence having at least 40% sequence identity with the amino acid / nucleotide / peptide sequence of any of the sequences mentioned herein, for example a sequence having 40% sequence identity with any of the sequences mentioned herein.

[0460] It is also envisioned that the amino acid / polynucleotide / polypeptide sequence has a sequence identity of greater than 65%, more preferably greater than 70%, even more preferably greater than 75%, and even more preferably greater than 80% with any of the above sequences. Preferably, the amino acid / nucleotide / polypeptide sequence has at least 85% identity, more preferably at least 90% identity, even more preferably at least 92% identity, even more preferably at least 95% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, and most preferably at least 99% identity with any of the sequences mentioned herein.

[0461] Those skilled in the art understand how to calculate the percent identity between two amino acid / polynucleotide / polypeptide sequences. In order to calculate the percent identity between two amino acid / polynucleotide / polypeptide sequences, an alignment of the two sequences must first be prepared and then the sequence identity values ​​calculated. The percent identity of two sequences can take different values ​​depending on: (i) the method used to align the sequences, e.g., ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or a structural alignment comparison from 3D; (ii) the parameters used by the alignment method, e.g., local alignment versus global alignment, the pair-scoring matrix used (e.g., BLOSUM62, PAM250, Gonnet, etc.) and the gap-penalty, e.g., the functional form and constant.

[0462] After an alignment has been made, there are many different ways to calculate the percent identity between two sequences. For example, the number of identical sequences can be divided by: (i) the length of the shortest sequence; (ii) the length of the alignment; (iii) the average length of the sequences; (iv) the number of non-gap positions; or (v) the number of equivalent positions excluding overhangs. In addition, it should be understood that the percent identity is also strongly dependent on length. Thus, the shorter a pair of sequences is, the higher the sequence identity one might expect to occur by chance.

[0463] Therefore, it can be appreciated that accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW (Thompson et al., 1994, Nucleic Acids Research, 224673-4680; Thompson et al., 1997, Nucleic Acids Research, 244876-4882) is the preferred method for generating protein or DNA multiple alignments according to the present invention. Suitable parameters for ClustalW may be as follows: For DNA alignments: Gap Open Penalty = 15.0, Gap Extension Penalty = 6.66, Matrix = Identity. For protein alignments: Gap Open Penalty = 10.0, Gap Extension Penalty = 0.2, Matrix = Gonnet. For DNA and protein alignments: ENDGAP = -1, GAPDIST = 4. Those skilled in the art will appreciate that it may be necessary to change these and other parameters to achieve optimal sequence alignment.

[0464] Preferably, then, the calculation of the percent identity between two amino acid / polynucleotide / polypeptide sequences can be calculated based on an alignment such as (N / T)*100, where N is the number of positions at which the sequences share the same residue and T is the total number of compared positions including gaps and including or excluding overhangs. Preferably, overhangs are included in the calculation. Thus, the most preferred method for calculating the percent identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters (e.g., as described above); and (ii) substituting the values ​​of N and T into the following formula: sequence identity=(N / T)*100.

[0465] Those skilled in the art will appreciate other alternative methods for identifying similar sequences. For example, substantially similar nucleotide sequences will be encoded by sequences that hybridize to a DNA sequence or its complement under stringent conditions. By stringent conditions, the inventors refer to hybridization to a filtration-bound DNA or RNA in 3x sodium chloride / sodium citrate (SSC) at about 45°C, followed by at least one wash in 0.2x SSC / 0.1% SDS at about 20°C-65°C. Alternatively, substantially similar polypeptides may differ from any of the sequences described above by at least 1 but less than 5, 10, 20, 50 or 100 amino acids.

[0466] Due to the degeneracy of the genetic code, it is obvious that any nucleic acid sequence described herein can be changed or altered without substantially affecting the protein sequence encoded thereby to provide a functional variant thereof. Suitable nucleotide variants are those having sequences that are altered by replacing different codons for the same amino acid in the coding sequence, thereby producing silent (synonymous) changes. Other suitable variants are those having homologous nucleotide sequences but comprising all or part of the sequence, which are altered by replacing different codons for the encoded amino acids with side chains having similar biophysical properties of the substituted amino acids, thereby producing conservative changes. For example, small non-polar hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar hydrophobic amino acids include phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include serine, threonine, cysteine, asparagine, and glutamine. Positively charged (basic) amino acids include lysine, arginine, and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Thus, it is understood which amino acids can be replaced with amino acids having similar biophysical properties, and those skilled in the art are aware of the nucleotide sequences encoding these amino acids.

[0467] All features described herein (including any accompanying claims, abstract and drawings) and / or all steps of any method or process so disclosed may be combined with any aspect described above in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. BRIEF DESCRIPTION OF THE DRAWINGS

[0468] In order to better understand the present invention and to show how to implement the embodiments of the present invention, a number of embodiments will be shown below and described in conjunction with the following drawings:

[0469] Figure 1 Affinity maturation strategies for developing antibody embodiments described herein are shown (Rajpal et al., 2005, PNAS 102: 24 8466-8471). Nine amino acids, i.e., alanine, serine, histidine, leucine, proline, tyrosine, aspartic acid, glutamine, and lysine, are selected and replaced at each CDR residue. Heavy variable chains (VH) and light variable chains (VL) are also shown, and their CDRs are highlighted in boxes, i.e., CDR-H1, CDR-H2, CDR-H3, and CDR-L1, CDR-L2, and CDR-L3.

[0470] Figure 2Shown is the screening result that screening 51B12 parent VH-CDR mutant produces supernatant in HTRF and ELISA mensuration.The production supernatant of dilution is tested.For ELISA, antibody binding is detected with anti-human IgG-HRP, and visualized with TMB.According to the position in CDR, the reactivity data is plotted on the x-axis from left to right, and is sorted alphabetically in CDR residue position (each CDR residue has n=8 or 9 mutants).The average HTRF signal of 51B12 parent antibody is shown in the figure by dotted line.

[0471] Figure 3 Shown is the screening result that 51B12 parent VL-CDR mutant produces supernatant in HTRF and ELISA mensuration.The production supernatant of dilution is tested.For ELISA, antibody binding is detected with anti-human IgG-HRP, and visualized with TMB.According to the position in CDR, the reactivity data is plotted on the x-axis from left to right, and is sorted alphabetically in CDR residue position (each CDR residue has n=8 or 9 mutants).The average HTRF signal of 51B12 parent antibody is shown in the figure by dotted line.

[0472] Figure 4 Several examples of selected antibody clones that exhibited reactive properties in the HTRF inhibition assay are shown.

[0473] Figure 5 Average data for control parental antibodies are shown.

[0474] Figure 6 Shown are data from a single cycle kinetic screen using huZIP12-ECD-GST ranging from 3.12 nM to 800 nM.

[0475] Figure 7 Shown are data from a single cycle kinetic screen of selected variants using huZIP12-ECD-GST ranging from 2.34 nM to 600 nM.

[0476] Figure 8 Epitope mapping of the 51B12 antibody is shown.

[0477] Figure 9a A table summarizing the six CDR, VH and VL sequences of the "51B12 parent" antibody is shown. Figure 9b Shown is a table summarizing the CDR, VH and VL sequences for each of the 26 different examples of affinity matured antibodies described herein.

[0478] Fig.10 Epitope mapping of affinity matured 51B12 W99H_L1 (also known as H3_W99H_L1) is shown. Fig.10a shows the binding at low concentration (5 ng / ml), Fig.10 b shows binding at higher concentration (lug / ml).

[0479] Fig.10 c shows the epitope candidate list of 51B12_W99H_L1.

[0480] Fig.11 Binding of antibodies 51B12, 63A11, 6B11, 38F02, 75E05 and 68G01 to CHO-K1 cells overexpressing ZIP12 is shown ( Fig.11 A in Figure 3), and internalization of antibodies 51B12 and 63A11 when detected with direct conjugation ( Fig.11 B).

[0481] Fig.12 Average data for binding of 51B12_W99H_L1 to human, cynomolgus monkey, canine and porcine ZIP12-ECD-GST are shown.

[0482] Fig.13 A set of histograms are shown showing the results of the Sugen model used to analyze the effect of 51B12_W99H_L1 administration on the reversal of pulmonary hypertension pathology. The bars in the figure represent the average activity for six animals.

[0483] Fig.14 The number of remodeled and occluded vessels after treatment with 51B12_W99H_L1 is shown ( Fig.14 A), and representative images of remodeled and occluded vessels and their reversal in the isotype control group and the 51B12_W99H_L1-treated group ( Fig.14 B). DETAILED DESCRIPTION

[0484] ZIP12 is implicated in the pathogenesis of pulmonary hypertension, and increased expression of ZIP12 is associated with the disease. Therefore, the inventors set out to develop antibodies that can specifically bind to and inhibit the function of ZIP12 to improve the treatment and diagnosis of pulmonary hypertension. The inventors took a ZIP12 binding antibody known as the 51B12 parent and affinity matured it to generate new variants that exhibit improved properties compared to the parent.

[0485] Materials and Methods

[0486] Cloning and expression

[0487] Cloning of 51B12 affinity matured variants

[0488] DNA expression constructs encoding antibodies were prepared de novo from overlapping oligonucleotides that included restriction sites for cloning into mammalian expression vectors and human signal sequences. Hindlll and Spel restriction sites were introduced to construct VH domains containing signal sequences for cloning into mammalian expression vectors containing a modified Fc null human gamma 1 constant region. Hindlll and BsiWI restriction sites were introduced to construct VL domains containing signal sequences for cloning into mammalian expression vectors containing human kappa constant regions.

[0489] Expression of recombinant antibodies (including antibody quantification)

[0490] The expression plasmids encoding the heavy and light chains were transiently co-transfected into HEK 293 6E cells and expressed on a small scale to produce antibodies. Antibodies were quantified by ELISA. ELISA plates were coated with 1 mg / ml anti-human IgG (Sigma I3382) and blocked with blocking solution (4% BSA in Tris-buffered saline). Tissue culture supernatant was added at different dilutions and the plates were incubated at room temperature for 1 hour. Dilutions of known standard antibodies were also added to the plates. The plates were washed in TBST and binding was detected by adding peroxidase-labeled anti-human kappa light chain antibodies (Sigma A7164) at a dilution of 1 / 1000 in blocking solution. After the plates were incubated at room temperature for 1 hour, they were washed with TBST. The plates were developed by adding OPD substrate (Sigma P9187) and stopped by adding 2M H2S04. The absorbance was measured at 490nm and a standard curve was drawn using the data of known standard dilutions. This standard curve was used to estimate the concentration of antibody in tissue culture supernatants. Larger scale antibodies were purified using protein A and the concentration was measured using a Nanodrop (Thermo Scientific).

[0491] Determination

[0492] ELISA experiments showed the binding of ZIP12 antibody to recombinant human ZIP12 protein.

[0493] hZIP12 ECD GST (5 μg / ml) was coated on ELISA plates, blocked and incubated with half-log dilution series of antibodies. Antibody binding was detected with anti-human IgG HRP and TMB. Protein coating was verified by staining with anti-ZIP12 and incubating with anti-rabbit IgG HRP and TMB.

[0494] HTRF experiments showing competition between parental and affinity-matured antibodies for recombinant human ZIP12 protein

[0495] Adopt homogeneous time-resolved fluorescence analysis (HTRF) to analyze antibody.Carry out checkerboard determination to verify the combination of terbium-labeled antibody and hZIP12-ECD-GST.The serial dilution of terbium-labeled 51B12 parent (half logarithmic dilution from 1000ng / ml) and the serial dilution of hZIP12-ECD-GST (half logarithmic dilution from 5000ng / ml) are incubated, and then incubated with anti-GST-XL665.After excitation (320nm), obtain emission signal and calculate HTRF ratio (665nm / 615nm, detection group A).Calculate signal / background ratio (S / B) based on HTRF ratio (0ng / ml hZIP12-ECD-GST as background signal), and draw Tb-51B12 parent concentration graph. The combination of 500ng / ml hZIP12-ECD-GST+50ng Tb-Ab, 150ng / ml hZIP12-ECD-GST+50ng Tb-Ab, and 50ng / ml hZIP12 ECD GST+50ng Tb-Ab were selected as the range for competition assay. For HTRF assay, 150ng / ml hZIP12-ECD-GST+30ng / ml Tb-51B12 was selected.

[0496] SPR experiment - single cycle kinetics

[0497] Single cycle kinetics (SCK) involves first capturing the mAb onto the protein A sensor surface, then sequentially injecting a series of concentrations of huZIP12-ECD-GST onto the surface starting with the lowest concentration and ending with the highest concentration. Reaching the final concentration is followed by a dissociation phase, where buffer is passed over the surface only, followed by regeneration, where the remaining bound huZIP12-ECD-GST is removed from the surface by injecting a 10 mM, pH 1.5 glycine and 50 mM NaOH solution. The SCK was repeated for each monoclonal antibody, providing replicate data, and the kinetics of each interaction was evaluated by Biacore software.

[0498] The concentration range of huZIP12-ECD-GST for injection was selected based on the affinity of the control mAb established in previous studies.

[0499] Data for each mAb were examined. Ideally, the concentration series of huZIP12-ECD-GST should reach approximately 80% saturation. At the highest concentration of huZIP12-ECD-GST tested, saturation was observed for some mAb samples. In the case of saturation, the concentration series of huZIP12-ECD-GST was reduced to obtain optimal binding kinetic data.

[0500] The parental clone 51B12_VH_VL-par was screened as a positive control at the beginning of each cycle of the SCK series and included in duplicate throughout the 17-hour run to provide a measure of sample stability during the 17-hour run.

[0501] Epitope mapping

[0502] Peptide sequences corresponding to the extracellular domain sequence of ZIP12 are directly synthesized using a carrier with a hydrogel matrix. This produces a highly sensitive array that can reliably detect even the weakest binding signals. These immobilized peptide arrays are reusable and can be tested multiple times. Therefore, this allows a series of antibodies or sera to be screened on a single array, making linear epitope mapping a rapid and cost-effective option for optimal candidate selection, antibody characterization, antibody repertoire analysis and further development.

[0503] Example 1: Generation of affinity matured variants

[0504] The present inventors took a candidate parent antibody, referred to as 51B12 parent (or 51B12 par), and affinity matured it to generate new variants or mutants that they hoped would exhibit improved properties compared to the parent.

[0505] like Figure 1 As shown, mutants with eight or nine CDR residues per CDR in the three heavy and light CDRs were designed using the method described by Rajpal et al., 2005. For the variable heavy chain (VH) CDR variants, the variable regions were synthesized and cloned into an expression vector containing Fc null human IgG1. For the variable light chain (VL) CDR variants, the variable regions were synthesized and cloned into an expression vector containing the human kappa light chain constant region.

[0506] Figure 9a The amino acid sequence of each of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3, VH and VL of the 51B12 parent is listed. Figure 9b A table is shown summarizing the sequences of 25 different affinity matured antibody embodiments from 51B12 parents. The first row in the table represents the corresponding sequences of affinity matured variants of 51B12 parent H3_W99H_L1, wherein the CDR-H3 sequence is identical to the corresponding sequence of the parent except for the W99H amino acid exchange, and the CDR-L1 CDR is as shown in the table. The second row in the table represents the corresponding sequences of affinity matured variants of 51B12 parent H3_W99H_L2, wherein the CDR-H3 sequence is identical to the corresponding sequence of the parent except for the W99H amino acid exchange, and the CDR-L2 CDR is as shown in the table, and so on.

[0507] Example 2: Screening of 51B12 variants / mutants

[0508] See also Figure 2 and Figure 3 , which shows the screening of 51B12 parent VH-CDRs ( Figure 2 ) and VL-CDR( Figure 3 ) mutant production supernatants. Diluted production supernatants were assayed. For ELISA, antibody binding was detected with anti-human IgG-HRP and visualized with TMB. Reactivity data were plotted from left to right along the x-axis according to position in the CDR and sorted alphabetically within the CDR residue positions (n=8 or 9 mutants per CDR residue). The average HTRF signal for the 51B12 parent antibody is shown as a dotted line in the figure.

[0509] Screening showed that amino acids G33, Y50, S53, W99, T100, Y103 and D106 in the heavy chain CDR are particularly important for target epitope recognition, as several clones with these amino acid substitutions resulted in loss of target recognition in both ELISA and HTRF assay formats. Amino acids A24, V29, Y36, H94, S95 and P99 in the light chain CDR are also particularly important for target recognition, as several clones with these amino acid substitutions also resulted in loss of target recognition in both ELISA and HTRF assay formats.

[0510] After extensive screening, it was decided to select 78 mutants for dose response screening. This decision was made based on experimental data from HTRF-based antibody concentration analysis and HTRF competition assays.

[0511] Example 3: Screening of 51B12 variants / mutants in a dose-response HTRF assay

[0512] Figure 4 Several examples of selected antibody clones that exhibited reactive properties in the HTRF inhibition assay are shown.

[0513] Compared with 51B12_VH_VL-par, clones H3_W99H_VL-par and H2_Y60K_L2 showed stronger inhibition in HTRF. Compared with 51B12_VH_VL-par, clones H3_M105P_L2 and H2_T63Y_VL-par showed slightly weaker inhibition. Clone H3_W99H_VL-par showed better response characteristics in all three assays. Then, heavy chain and light chain sequences were selected and combined to prepare 27 affinity matured antibodies, which were then measured in SPR assays.

[0514] Example 4: Screening of purified affinity matured antibodies in SPR assay

[0515] See also Figure 5 , which shows the average data of the control 51B12_VH_VL-parent antibody.

[0516] See also Figure 6 , which shows the kinetic parameters obtained for all antibody variants when screened with 3.12nM-800nM huZIP12-ECD-GST. The data show that the binding ratios (ka) of variants H3_W99H_L1, H3_W99H_L2 and H3_W99H_par are better than those of the parent antibody 51B12_par (e.g. Figure 5 The binding ratios of antibodies H2_T57H_L1, H2_Y60K_L1, H2_T63Y_L1, H2_K65P_L1, H2_G66Q_L1, H3_M105P_L1, 51B12_VH_L1, H2_T57H_L2, H2_Y60K_L2, H2_G66Q_L2, H2_T57H_VL_par, H2_Y60K_VL_par, H2_T63Y_VL_par and H2_G66Q_VL_par were also better than the parent antibody. Affinity. Figure 6 All antibodies listed in showed excellent dissociation ratios (kd). In particular, antibodies H3_W99H_L1, H3_W99H_L2 and H3_W99H_par showed excellent binding affinities, defined as KD (M).

[0517] It can be seen that the three antibody variants, H3_W99H_L1, H3_W99HL2 and H3_W99H_VL-par, all appear to have a higher affinity (KD) of about 500 pM.

[0518] A series of high affinity antibody variants were re-assayed at a relatively lower concentration series and with extended dissociation times in order to better assess their binding kinetics. Figure 7 , which shows data for monoclonal antibodies that were re-assayed to optimize binding kinetic data. Again, the three antibody variants H3_W99H_L1, H3_W99HL2, and H3_W99H_VL-par all showed higher affinities than the parent antibody. The binding ratio (ka), dissociation ratio (kd), and overall affinity measure (KD) were all improved compared to the 51B12 VH_VL_par parent antibody. The affinity of the affinity matured variants was about 300 pM, compared to 1.1 nM for the parent antibody (e.g., Figure 7 ).

[0519] Example 5: Epitope mapping

[0520] The inventors then set out to determine the precise epitope on the extracellular sequence of the ZIP12 protein to which the antibody variants bound.

[0521] Figure 8 The graph shown compares the binding properties of the samples (51B12 variant antibodies, whose interaction strength is shown in blue bars) with the isotype control samples (human IgG1 Fc null, whose interaction strength is shown in red bars) under the same conditions (in PBST buffer). Linear (LIN10 and LIN15) and circular (LOOP10, LOOP15) overlapping peptides were generated based on the human ZIP12 extracellular domain sequence (as well as HELix 19 and BETa sheet 22) and immobilized on the hydrogel matrix. The peptides are defined as follows:

[0522] LIN10 = 10mer linear peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8 The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-10, so the last residue number is 10, and so on.

[0523] LIN15 = 15mer linear peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8 The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-15, so the last residue number is 15, and so on.

[0524] LOOP10 = 10mer peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8 The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-10, so the last residue number is 10, etc. The LOOP peptide differs from the LIN peptide in that it is structurally fixed into a defined single loop structure using CLIPS scaffolding technology (Pepscan).

[0525] LOOP15 = 15mer peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8 The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-15, so the last residue number is 15, etc. The LOOP peptide differs from the LIN peptide in that it is structurally fixed into a defined single loop structure using CLIPS scaffolding technology (Pepscan).

[0526] HEL19 = 19mer peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-19, so the last residue number is 19, etc. The HEL peptide is different from the LIN peptide because it is structurally fixed into a defined alpha helical structure using CLIPS scaffolding technology (Pepscan).

[0527] BET22 = 22mer peptide starting at position 1 of the ZIP12 extracellular domain. Figure 8 The position on the y-axis is defined as the last residue number of the peptide. For example, peptide 1 covers amino acids 1-22, so the last residue number is 22, etc. BET peptides differ from LIN peptides in that they are structurally fixed to a defined beta-fold structure using CLIPS scaffolding technology (Pepscan).

[0528] Linear and conformational epitopes were explored using both linear and structurally defined peptides. Figure 8 As shown, the antibody binding to each peptide was measured and plotted. For sample 51B12 antibody, strong binding peaks were observed in both linear peptides (LIN10 and LIN15) between amino acids 46-63 and conformational peptides (LOOP10, LOOP15, HEL19, BET22), but no such strong binding peaks were observed in the isoforms. Figure 8 The data obtained in the present study determined that the epitope of the 51B12 antibody variants is at least partially linear. Figure 8 The peptides that showed higher intensity than the isotype control in the above assays are epitope candidates for the 51B12 antibody. The antibody was functionally active in the Zn-FLIPR assay, indicating that it inhibits Zn 2+ transport.

[0529] The sequence of the epitope is: ADLLQVLSAGDHPPHNHSRS [SEQ ID No: 252].

[0530] More preferably, the sequence of the epitope is: LLQVLSAGDHPPHNHSRS [SEQ ID No: 1].

[0531] Example 6: Epitope mapping of affinity matured antibodies

[0532] In order to reconstruct the epitope of the target molecule, a peptide-based mimetic library was synthesized using Fmoc-based solid phase peptide synthesis. Amino-functionalized polypropylene supports were obtained by grafting with a proprietary hydrophilic polymer formulation, followed by reaction with dicyclohexylcarbodiimide (DCC) and N-hydroxybenzotriazole (HOBt) and tert-butyloxycarbonylhexanediamine (BocHMDA), followed by cleavage of the Boc group using trifluoroacetic acid (TFA). Peptides were synthesized on amino-functionalized solid supports using standard Fmoc peptide synthesis using a custom-made modified JANUS liquid handling station (Perkin Elmer).

[0533] Different peptide groups were designed as follows:

[0534] Table 1

[0535] Group 1 LIN10 A linear peptide of length 10 derived from the ECD human ZIP12 target sequence Group 2 LIN15 A linear peptide of length 15 derived from the ECD human ZIP12 target sequence Group 3 LOOP10 Constrained peptide of length 10. 8-mer peptide bound at positions 2-9 Group 4 LOOP15 Constrained peptide of length 15. 13-mer peptide bound at positions 2-14 Group 5 BET22 β-turn peptide mimetic of length 22. Positions 2-21 are derived 20-mer peptides Group 6 HEL19 19-length α-helical peptide mimetic derived from target residues

[0536] The binding of the antibodies to each synthetic peptide was tested in a peptide-based ELISA. The peptide array was incubated with the primary antibody solution (overnight at 4°C). After washing, the peptide array was incubated with the appropriate antibody-peroxidase conjugate at a 1 / 1000 dilution at 25°C for 1 hour. After washing, 2,2'-azino-bis-3-ethylbenzdihydrothiazoline-6-sulfonic acid (ABTS) as a peroxidase substrate and 20 μl / ml of 3% H2O2 were added. After one hour, the color development was measured. The color development was quantified using a charge-coupled device camera and image processing system.

[0537] Sample 907672.1 (51B12 W99H_L1, also referred to as H3_W99H_L1) was screened under a variety of different conditions. Specific binders were consistently observed in the various screens for the amino acid region 35-48. Even at very low concentrations (e.g., 5 ng / ml), the samples showed strong binding to this specific region of the peptide. Fig.10 A in Fig.10 As shown in Figure A, the strong binders identified in region 35-48 did not show a distinct peak in the LIN10 and LOOP10 peptide mimetics, each of which contained a peptide consisting of 10 residues. At higher concentrations, several additional binding peaks were observed by linear and conformational mapping, which were different from the isotype control ( Fig.10 B). These binding peaks were identified as minor epitope candidates because they were only present at higher concentrations. These binders are likely nonspecific.

[0538] To identify sample-specific binders, isotype controls were screened under similar conditions. Binding peaks that differed from the isotype control were selected based on the criterion that the sample peptide intensity was at least 4 times the control peptide intensity. Fig.10 As shown in A, the high intensity binders identified in region 35-48 did not show obvious peaks in the LIN10 and LOOP10 peptide mimetics, each of which contained a peptide consisting of 10 residues.

[0539] Fig.10 C in FIG. 5 shows a list of epitope candidates for 51B12_W99H_L1.

[0540] Example 7: Internalization of 51B12_W99H_L1 in cells overexpressing the full-length ZIP12 protein

[0541] Internalization of antibodies was measured over time using direct binding flow cytometry. The following antibodies were selected for internalization testing: 51B12, 63A11, 6B11, 38F02, 75E05, and 68G01.

[0542] Fig.11 Panel A shows that antibodies 51B12, 63A11, 6B11, 38F02, 75E05, and 68G01 bind to CHO-K1 cells overexpressing ZIP12, as expected. These antibodies were not tested further. Fig.11 B in Figure 3 shows the internalization of antibodies 51B12 and 63A11 measured using the direct binding method. Only a slight difference in internalization rate was observed between 51B12 and 63A11. No direct binding internalization was observed for 6B11 or 38F02.

[0543] Example 8: 51B12_W99H_L1 binds to human and cynomolgus monkey ZIP12-GST-ECD, but not to canine or porcine proteins Fork reaction

[0544] Surface plasmon resonance (SPR) is a label-free biophysical technique that can directly measure the interaction between biomolecules. A single-cycle kinetic (SCK) SPR direct binding assay was developed to characterize the binding of antibodies to human, cynomolgus monkey, porcine and canine ZIP12 fusion proteins. The assay was used to characterize the binding kinetics of the monoclonal antibody 51B12_W99H_L1 to each of the four proteins (defined by kon, koff, KD). Single-cycle kinetics (SCK) involves first capturing the mAb onto the protein A sensor surface, and then sequentially injecting a series of concentrations of huZIP12-ECD-GST on the surface starting with the lowest concentration and ending with the highest concentration. After reaching the final concentration, there is a dissociation phase, in which the buffer is passed only through the surface, followed by regeneration, in which the remaining bound huZIP12-ECD-GST is removed from the surface by injecting 10mM, pH 1.5 glycine and 50mM NaOH solutions. SCK is repeated for each monoclonal antibody, providing repeated data, and the kinetics of each interaction are evaluated by Biacore software.

[0545] Fig.12 The average data of 51B12_W99H_L1 binding to human, cynomolgus monkey, pig and dog ZIP12-ECD-GST are shown. 51B12_W99H_L1 binds to human and cynomolgus monkey proteins respectively, and the two bindings have similar ka, kd and KD (4.02x10 -9 and 6.31x10 -9 ).

[0546] Example 9: 51B12_W99H_L1 reverses pulmonary arterial hypertension (PAH) pathology in the Sugen lung remodeling model

[0547] Fig.13A set of histograms are shown showing the results of the Sugen model used to analyze the effects of 51B12_W99H_L1 administration on the reversal of pulmonary hypertension pathology. Humanized ZIP12 Sprague-Dawley rats were treated with 20 mg / kg Sugen5416 and placed in a hypoxic chamber with an oxygen level of 10%. The rats were left in the chamber for 24 days and then returned to room air for 8 days. After this, PAH pathology is expected to have developed. The rats were then randomly divided into two groups and treated with 10 mg / kg human IgG1 isotype control antibody (control group) and 10 mg / kg 51B12_W99H_L1, respectively. In order to quantify the reversal of PAH pathology, multiple hemodynamic measurements were performed. The bars in the figure represent the average activity for six animals.

[0548] Fig.13 Humanized rats treated with 51B12_W99H_L1 showed a decrease in mean pulmonary artery pressure (mPAP) compared to isotype controls. Rats treated with 51B12_W99H_L1 also showed a decrease in right ventricular hypertrophy compared to rats treated with isotype controls.

[0549] Fig.14 a shows that the number of remodeled and occluded vessels decreased after 51B12_W99H_L1 treatment. Remodeled vessels are those vessels of the pulmonary vasculature that show thickening of the vessel wall, and occluded vessels are those that are closed.

[0550] Fig.14 b shows representative examples of remodeled and occluded vessels and their reversal in the isotype control group and the 51B12_W99H_L1 treated group. Remodeled vessels are indicated by black closed arrows, and occluded vessels are indicated by open arrows.

[0551] in conclusion

[0552] In summary, the inventors took a ZIP12 binding antibody called 51B12 parent and affinity matured it to generate a series of 26 new variants. Figure 8 As shown, using epitope mapping, the inventors accurately determined the epitope on the extracellular domain of ZIP12 to which these antibodies bind. In addition, the variant antibodies have surprisingly high binding affinity to this epitope, with improvements in binding ratio (ka), dissociation ratio (kd) and total affinity (KD). In addition, these variants are functionally active in the Zn FLIPR assay, indicating that they inhibit zinc ion transport. Therefore, these antibodies will be powerful candidate therapeutic drugs for treating, preventing or ameliorating hypoxia-related disorders (e.g., pulmonary hypertension or cancer).

Claims

1. An antibody or an antigen-binding fragment thereof, which specifically binds to the extracellular domain of ZIP12 and recognizes an epitope comprising ADLLQVLSAGDHPPHNHSRS (SEQ ID No: 252) or a variant or fragment thereof or consisting of ADLLQVLSAGDHPPHNHSRS or a variant or fragment thereof.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody or its antigen-binding fragment recognizes: (i) an epitope comprising LLQVLSAGDHPPHNHSRS (SEQ ID No: 1) or a variant or fragment thereof, or an epitope consisting of LLQVLSAGDHPPHNHSRS or a variant or fragment thereof; or (ii) an epitope comprising ADLLQ (SEQ ID No: 253) or a variant or fragment thereof, or an epitope consisting of ADLLQ or a variant or fragment thereof.

3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein The antibody or antigen-binding fragment thereof does not substantially bind to human ZIP4 and / or ZIP13.

4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein The antibody or antigen-binding fragment thereof comprises: (i) a CDR-H1 domain comprising or consisting of SEQ ID No: 13, a CDR-H2 domain comprising or consisting of SEQ ID No: 14, a CDR-H3 domain comprising or consisting of SEQ ID No: 15, a CDR-L1 domain comprising or consisting of SEQ ID No: 16, a CDR-L2 domain comprising or consisting of SEQ ID No: 17, and a CDR-L3 domain comprising or consisting of SEQ ID No: 18; (ii) a CDR-H1 domain comprising or consisting of SEQ ID No: 21, a CDR-H2 domain comprising or consisting of SEQ ID No: 22, a CDR-H3 domain comprising or consisting of SEQ ID No: 23, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26; (iii) a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 33, and a CDR-L3 domain comprising or consisting of SEQ ID No: 34; (iv) a CDR-H1 domain comprising or consisting of SEQ ID No: 37, a CDR-H2 domain comprising or consisting of SEQ ID No: 38, a CDR-H3 domain comprising or consisting of SEQ ID No: 39, a CDR-L1 domain comprising or consisting of SEQ ID No: 40, a CDR-L2 domain comprising or consisting of SEQ ID No: 41, and a CDR-L3 domain comprising or consisting of SEQ ID No: 42; (v) a CDR-H1 domain comprising or consisting of SEQ ID No: 45, a CDR-H2 domain comprising or consisting of SEQ ID No: 46, a CDR-H3 domain comprising or consisting of SEQ ID No: 47, a CDR-L1 domain comprising or consisting of SEQ ID No: 48, a CDR-L2 domain comprising or consisting of SEQ ID No: 49, and a CDR-L3 domain comprising or consisting of SEQ ID No: 50; (vi) a CDR-H1 domain comprising or consisting of SEQ ID No:53, a CDR-H2 domain comprising or consisting of SEQ ID No:54, a CDR-H3 domain comprising or consisting of SEQ ID No:55, a CDR-L1 domain comprising or consisting of SEQ ID No:56, a CDR-L2 domain comprising or consisting of SEQ ID No:57, and a CDR-L3 domain comprising or consisting of SEQ ID No:58; (vii) a CDR-H1 domain comprising or consisting of SEQ ID No: 61, a CDR-H2 domain comprising or consisting of SEQ ID No: 62, a CDR-H3 domain comprising or consisting of SEQ ID No: 63, a CDR-L1 domain comprising or consisting of SEQ ID No: 64, a CDR-L2 domain comprising or consisting of SEQ ID No: 65, and a CDR-L3 domain comprising or consisting of SEQ ID No: 66; (viii) a CDR-H1 domain comprising or consisting of SEQ ID No: 69, a CDR-H2 domain comprising or consisting of SEQ ID No: 70, a CDR-H3 domain comprising or consisting of SEQ ID No: 71, a CDR-L1 domain comprising or consisting of SEQ ID No: 72, a CDR-L2 domain comprising or consisting of SEQ ID No: 73, and a CDR-L3 domain comprising or consisting of SEQ ID No: 74; (ix) a CDR-H1 domain comprising or consisting of SEQ ID No: 77, a CDR-H2 domain comprising or consisting of SEQ ID No: 78, a CDR-H3 domain comprising or consisting of SEQ ID No: 79, a CDR-L1 domain comprising or consisting of SEQ ID No: 80, a CDR-L2 domain comprising or consisting of SEQ ID No: 81, and a CDR-L3 domain comprising or consisting of SEQ ID No: 82; (x) a CDR-H1 domain comprising or consisting of SEQ ID No: 85, a CDR-H2 domain comprising or consisting of SEQ ID No: 86, a CDR-H3 domain comprising or consisting of SEQ ID No: 87, a CDR-L1 domain comprising or consisting of SEQ ID No: 88, a CDR-L2 domain comprising or consisting of SEQ ID No: 89, and a CDR-L3 domain comprising or consisting of SEQ ID No: 90; (xi) a CDR-H1 domain comprising or consisting of SEQ ID No: 93, a CDR-H2 domain comprising or consisting of SEQ ID No: 94, a CDR-H3 domain comprising or consisting of SEQ ID No: 95, a CDR-L1 domain comprising or consisting of SEQ ID No: 96, a CDR-L2 domain comprising or consisting of SEQ ID No: 97, and a CDR-L3 domain comprising or consisting of SEQ ID No: 98; (xii) a CDR-H1 domain comprising or consisting of SEQ ID No: 101, a CDR-H2 domain comprising or consisting of SEQ ID No: 102, a CDR-H3 domain comprising or consisting of SEQ ID No: 103, a CDR-L1 domain comprising or consisting of SEQ ID No: 104, a CDR-L2 domain comprising or consisting of SEQ ID No: 105, and a CDR-L3 domain comprising or consisting of SEQ ID No: 106; (xiii) a CDR-H1 domain comprising or consisting of SEQ ID No: 109, a CDR-H2 domain comprising or consisting of SEQ ID No: 110, a CDR-H3 domain comprising or consisting of SEQ ID No: 111, a CDR-L1 domain comprising or consisting of SEQ ID No: 112, a CDR-L2 domain comprising or consisting of SEQ ID No: 113, and a CDR-L3 domain comprising or consisting of SEQ ID No: 114; (xiv) a CDR-H1 domain comprising or consisting of SEQ ID No: 117, a CDR-H2 domain comprising or consisting of SEQ ID No: 118, a CDR-H3 domain comprising or consisting of SEQ ID No: 119, a CDR-L1 domain comprising or consisting of SEQ ID No: 120, a CDR-L2 domain comprising or consisting of SEQ ID No: 121, and a CDR-L3 domain comprising or consisting of SEQ ID No: 122; (xv) a CDR-H1 domain comprising or consisting of SEQ ID No: 125, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, a CDR-H3 domain comprising or consisting of SEQ ID No: 127, a CDR-L1 domain comprising or consisting of SEQ ID No: 128, a CDR-L2 domain comprising or consisting of SEQ ID No: 129, and a CDR-L3 domain comprising or consisting of SEQ ID No: 130; (xvi) a CDR-H1 domain comprising or consisting of SEQ ID No: 133, a CDR-H2 domain comprising or consisting of SEQ ID No: 134, a CDR-H3 domain comprising or consisting of SEQ ID No: 135, a CDR-L1 domain comprising or consisting of SEQ ID No: 136, a CDR-L2 domain comprising or consisting of SEQ ID No: 137, and a CDR-L3 domain comprising or consisting of SEQ ID No: 138; (xvii) a CDR-H1 domain comprising or consisting of SEQ ID No: 141, a CDR-H2 domain comprising or consisting of SEQ ID No: 142, a CDR-H3 domain comprising or consisting of SEQ ID No: 143, a CDR-L1 domain comprising or consisting of SEQ ID No: 144, a CDR-L2 domain comprising or consisting of SEQ ID No: 145, and a CDR-L3 domain comprising or consisting of SEQ ID No: 146; (xviii) a CDR-H1 domain comprising or consisting of SEQ ID No: 149, a CDR-H2 domain comprising or consisting of SEQ ID No: 150, a CDR-H3 domain comprising or consisting of SEQ ID No: 151, a CDR-L1 domain comprising or consisting of SEQ ID No: 152, a CDR-L2 domain comprising or consisting of SEQ ID No: 153, and a CDR-L3 domain comprising or consisting of SEQ ID No: 154; (xix) a CDR-H1 domain comprising or consisting of SEQ ID No: 157, a CDR-H2 domain comprising or consisting of SEQ ID No: 158, a CDR-H3 domain comprising or consisting of SEQ ID No: 159, a CDR-L1 domain comprising or consisting of SEQ ID No: 160, a CDR-L2 domain comprising or consisting of SEQ ID No: 161, and a CDR-L3 domain comprising or consisting of SEQ ID No: 162; (xx) a CDR-H1 domain comprising or consisting of SEQ ID No: 165, a CDR-H2 domain comprising or consisting of SEQ ID No: 166, a CDR-H3 domain comprising or consisting of SEQ ID No: 167, a CDR-L1 domain comprising or consisting of SEQ ID No: 168, a CDR-L2 domain comprising or consisting of SEQ ID No: 169, and a CDR-L3 domain comprising or consisting of SEQ ID No: 170; (xxi) a CDR-H1 domain comprising or consisting of SEQ ID No: 173, a CDR-H2 domain comprising or consisting of SEQ ID No: 174, a CDR-H3 domain comprising or consisting of SEQ ID No: 175, a CDR-L1 domain comprising or consisting of SEQ ID No: 176, a CDR-L2 domain comprising or consisting of SEQ ID No: 177, and a CDR-L3 domain comprising or consisting of SEQ ID No: 178; (xxii) a CDR-H1 domain comprising or consisting of SEQ ID No: 181, a CDR-H2 domain comprising or consisting of SEQ ID No: 182, a CDR-H3 domain comprising or consisting of SEQ ID No: 183, a CDR-L1 domain comprising or consisting of SEQ ID No: 184, a CDR-L2 domain comprising or consisting of SEQ ID No: 185, and a CDR-L3 domain comprising or consisting of SEQ ID No: 186; (xxiii) a CDR-H1 domain comprising or consisting of SEQ ID No: 189, a CDR-H2 domain comprising or consisting of SEQ ID No: 190, a CDR-H3 domain comprising or consisting of SEQ ID No: 191, a CDR-L1 domain comprising or consisting of SEQ ID No: 192, a CDR-L2 domain comprising or consisting of SEQ ID No: 193, and a CDR-L3 domain comprising or consisting of SEQ ID No: 194; (xxiv) a CDR-H1 domain comprising or consisting of SEQ ID No: 197, a CDR-H2 domain comprising or consisting of SEQ ID No: 198, a CDR-H3 domain comprising or consisting of SEQ ID No: 199, a CDR-L1 domain comprising or consisting of SEQ ID No: 200, a CDR-L2 domain comprising or consisting of SEQ ID No: 201, and a CDR-L3 domain comprising or consisting of SEQ ID No: 202; (xxv) a CDR-H1 domain comprising or consisting of SEQ ID No: 205, a CDR-H2 domain comprising or consisting of SEQ ID No: 206, a CDR-H3 domain comprising or consisting of SEQ ID No: 207, a CDR-L1 domain comprising or consisting of SEQ ID No: 208, a CDR-L2 domain comprising or consisting of SEQ ID No: 209, and a CDR-L3 domain comprising or consisting of SEQ ID No: 210; or (xxvi) a CDR-H1 domain comprising or consisting of SEQ ID No: 213, a CDR-H2 domain comprising or consisting of SEQ ID No: 214, a CDR-H3 domain comprising or consisting of SEQ ID No: 215, a CDR-L1 domain comprising or consisting of SEQ ID No: 216, a CDR-L2 domain comprising or consisting of SEQ ID No: 217, and a CDR-L3 domain comprising or consisting of SEQ ID No:

218.

5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein The antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region comprising or consisting of SEQ ID No: 19 and a light chain variable region comprising or consisting of SEQ ID No: 20; (ii) a heavy chain variable region comprising or consisting of SEQ ID No: 27 and a light chain variable region comprising or consisting of SEQ ID No: 28; (iii) a heavy chain variable region comprising or consisting of SEQ ID No: 35 and a light chain variable region comprising or consisting of SEQ ID No: 36; (iv) a heavy chain variable region comprising or consisting of SEQ ID No: 43 and a light chain variable region comprising or consisting of SEQ ID No: 44; (v) a heavy chain variable region comprising or consisting of SEQ ID No: 51 and a light chain variable region comprising or consisting of SEQ ID No: 52; (vi) a heavy chain variable region comprising or consisting of SEQ ID No: 59 and a light chain variable region comprising or consisting of SEQ ID No: 60; (vii) a heavy chain variable region comprising or consisting of SEQ ID No: 67 and a light chain variable region comprising or consisting of SEQ ID No: 68; (viii) a heavy chain variable region comprising or consisting of SEQ ID No: 75 and a light chain variable region comprising or consisting of SEQ ID No: 76; (ix) a heavy chain variable region comprising or consisting of SEQ ID No: 83 and a light chain variable region comprising or consisting of SEQ ID No: 84; (x) a heavy chain variable region comprising or consisting of SEQ ID No: 91 and a light chain variable region comprising or consisting of SEQ ID No: 92; (xi) a heavy chain variable region comprising or consisting of SEQ ID No: 99 and a light chain variable region comprising or consisting of SEQ ID No: 100; (xii) a heavy chain variable region comprising or consisting of SEQ ID No: 107 and a light chain variable region comprising or consisting of SEQ ID No: 108; (xiii) a heavy chain variable region comprising or consisting of SEQ ID No: 115 and a light chain variable region comprising or consisting of SEQ ID No: 116; (xiv) a heavy chain variable region comprising or consisting of SEQ ID No: 123 and a light chain variable region comprising or consisting of SEQ ID No: 124; (xv) a heavy chain variable region comprising or consisting of SEQ ID No: 131 and a light chain variable region comprising or consisting of SEQ ID No: 132; (xvi) a heavy chain variable region comprising or consisting of SEQ ID No: 139 and a light chain variable region comprising or consisting of SEQ ID No: 140; (xvii) a heavy chain variable region comprising or consisting of SEQ ID No: 147 and a light chain variable region comprising or consisting of SEQ ID No: 148; (xviii) a heavy chain variable region comprising or consisting of SEQ ID No: 155 and a light chain variable region comprising or consisting of SEQ ID No: 156; (xix) a heavy chain variable region comprising or consisting of SEQ ID No: 163 and a light chain variable region comprising or consisting of SEQ ID No: 164; (xx) a heavy chain variable region comprising or consisting of SEQ ID No: 171 and a light chain variable region comprising or consisting of SEQ ID No: 172; (xxi) a heavy chain variable region comprising or consisting of SEQ ID No: 179 and a light chain variable region comprising or consisting of SEQ ID No: 180; (xxii) a heavy chain variable region comprising or consisting of SEQ ID No: 187 and a light chain variable region comprising or consisting of SEQ ID No: 188; (xxiii) a heavy chain variable region comprising or consisting of SEQ ID No: 195 and a light chain variable region comprising or consisting of SEQ ID No: 196; (xxiv) a heavy chain variable region comprising or consisting of SEQ ID No: 203 and a light chain variable region comprising or consisting of SEQ ID No: 204; (xxv) a heavy chain variable region comprising or consisting of SEQ ID No: 211 and a light chain variable region comprising or consisting of SEQ ID No: 212; or (xxvi) a heavy chain variable region comprising or consisting of SEQ ID No: 219 and a light chain variable region comprising or consisting of SEQ ID No:

220.

6. An antibody or antigen-binding fragment thereof, wherein: The antibodies or antigen-binding fragments thereof specifically bind to ZIP12 and include six CDR sequences as shown in FIG. 9b for each antibody.

7. The antibody or antigen-binding fragment thereof according to claim 6, wherein The antibodies or antigen-binding fragments thereof comprise a VH / VL sequence pair as shown for each antibody in FIG. 9b .

8. The antibody or antigen-binding fragment thereof according to claim 6 or 7, wherein The antibody or antigen-binding fragment thereof specifically binds to the extracellular domain of ZIP12 and recognizes an epitope comprising or consisting of ADLLQVLSAGDHPPHNHSRS (SEQ ID No: 252).

9. The antibody or antigen-binding fragment thereof according to claim 8, wherein The antibody or antigen-binding fragment thereof heterosexually binds to the extracellular domain of ZIP12 and recognizes an epitope comprising or consisting of LLQVLSAGDHPPHNHSRS (SEQ ID No: 1).

10. Use of the antibody or antigen-binding fragment thereof as claimed in any one of claims 1 to 9 in therapy.

11. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 in treating, preventing or ameliorating hypoxia-related diseases.

12. The use of the antibody or antigen-binding fragment thereof according to claim 11, wherein: The hypoxia-related disorder is pulmonary hypertension or cancer.

13. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, and optionally a pharmaceutically acceptable carrier.

14. A method for preparing the pharmaceutical composition of claim 13, comprising combining a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1 to 9 with a pharmaceutically acceptable carrier.

15. An antibody or antigen-binding fragment thereof obtained by the following method, the method comprising: (i) immunizing a host organism with an extracellular epitope of ZIP12, wherein the extracellular epitope of ZIP12 comprises or consists of SEQ ID No: 252 or SEQ ID No: 1 or a variant or fragment thereof; and (ii) collecting the antibody or antigen-binding fragment thereof from the host.

16. A polynucleotide sequence encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

17. An expression cassette comprising the polynucleotide sequence of claim 16. A recombinant vector comprising the expression cassette according to claim 17 .

19. A host cell comprising the polynucleotide sequence of claim 16, the expression cassette of claim 17, or the recombinant vector of claim 18.

20. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the method comprising: a) introducing the recombinant vector according to claim 18 into a host cell; as well as b) culturing the host cell under conditions capable of producing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

21. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 in diagnosis or prognosis.

22. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 in diagnosing or prognosing a hypoxia-related disease.

23. A method for diagnosing or prognosing a hypoxia-related disorder in a subject, the method comprising detecting ZIP12 in a biological sample obtained from the subject using the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

24. A kit for diagnosing a subject suffering from a hypoxia-related disorder or for providing a prognosis of the disorder of the subject, the kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, for detecting ZIP12 in a sample from the subject.

25. The use according to claim 21, the method according to claim 23, or the kit according to claim 24, wherein: The hypoxia-related condition is pulmonary hypertension or cancer.